邢唷>? ?e??  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdf?ghijklmnopqrstuvwxyz{|}~€Root Entry F||萒?鄁=1€Workbook?ETExtDataSummaryInformation( ???? n韖Km?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?鄥燆鵒h珣+'迟0@ g2蓘\p Windows (u7b Ba==鶳?8X@"1 I{縹1 I{縹1 I{縹1 I{縹1 媅SO1 I{縹1 I{縹1" N媅_GB23121" N媅_GB23121 I{縹1 I{縹1" N媅_GB23121" N媅_GB23121 I{縹1 I{縹1 h6 I{縹 Light1,6 I{縹16 I{縹16 I{縹1 I{縹1 I{縹1 I{縹1 I{縹14 I{縹1  I{縹1 I{縹1  I{縹14 I{縹1  I{縹1< I{縹1? I{縹1> I{縹1 I{縹1 I{縹1 I{縹1 wiSO1" N媅_GB23121" N媅_GB23121h Rz個{h媅1 Rz個{h媅1" N媅_GB2312"?#,##0;"?\-#,##0"?#,##0;[Red]"?\-#,##0"?#,##0.00;"?\-#,##0.00#"?#,##0.00;[Red]"?\-#,##0.007*2_ "?* #,##0_ ;_ "?* \-#,##0_ ;_ "?* "-"_ ;_ @_ .))_ * #,##0_ ;_ * \-#,##0_ ;_ * "-"_ ;_ @_ ?,:_ "?* #,##0.00_ ;_ "?* \-#,##0.00_ ;_ "?* "-"??_ ;_ @_ 6+1_ * #,##0.00_ ;_ * \-#,##0.00_ ;_ * "-"??_ ;_ @_ \$#,##0_);\(\$#,##0\)\$#,##0_);[Red]\(\$#,##0\) \$#,##0.00_);\(\$#,##0.00\)% \$#,##0.00_);[Red]\(\$#,##0.00\) 000000? ? ? ? ? ? ? ? ? ? ? ? ? ? ?   ? ?/ ? ? ? ?* ?, ?/ ? ?+ ?, ?+ ?1 ?/ ? ?+ ?, ?9  ? ? ?P ?P ? € ? ?- ? ? ?* ?a> ,? *? ?  ?攆f7 ? ? ?` +? )? ?> ?5 ?7 ?3 ?1 ?9 ?+ ?  ? / !? ?    @ " H " h  `@ @  x@ @  x@ @ # H #   x@ @  |@ @  x@ @  @ @ x@ @  x@ @  $8  x@ @  x@ @  " %8@ &8@ x@ @  x@ @ 'x@ @  ( )x@ @  )8  ||[瞡}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-} .00\)_ *}-} .00\)_ *}-} .00\)_ *}-} .00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}A}.00\)_ *ef;_ @_ }A}.00\)_ *ef;_ @_ }A}.00\)_ *ef;_ @_ }A}.00\)_ *ef;_ @_ }A}.00\)_ *ef;_ @_ }A}.00\)_ *ef ;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈 ;_ @_ }A}.00\)_ *23;_ @_ }A}.00\)_ *23;_ @_ }A}.00\)_ *23;_ @_ }A}.00\)_ *23;_ @_ }A} .00\)_ *23;_ @_ }A}!.00\)_ *23 ;_ @_ }-}".00\)_ *}-}#.00\)_ *}A}$.00\)_ *;_ @_ }A}%.00\)_ *?;_ @_ }A}&.00\)_ *23;_ @_ }-}'.00\)_ *}A}(.00\)_ *俏;_ @_ }-}* .00\)_ *}A}+a.00\)_ *骑?;_ @_ }U},.00\)_ *;_ @_  }-}-.00\)_ *}-}..00\)_ *}}/鷠.00\)_ *蝌?;_ @_    }}0.00\)_ *ゥ?;_ @_ ??? ??? ??? ???}-}1.00\)_ *}-}2.00\)_ *}A}3鷠.00\)_ *€;_ @_ }-}4.00\)_ *}-}5.00\)_ *}A}6.00\)_ *;_ @_ }A}7.00\)_ *;_ @_ }A}8.00\)_ *;_ @_ }A}9.00\)_ *;_ @_ }A}:.00\)_ *;_ @_ }A};.00\)_ * ;_ @_ }A}<淲.00\)_ *霚;_ @_ }}=???.00\)_ *蝌?;_ @_ ??? ??? ??? ???}}>??v.00\)_ *虣;_ @_    }-}? .00\)_ *}}@.00\)_ *?;_ @_ 膊? 膊? 膊? 膊?}-}A.00\)_ *}}B}}C}-}D.00\)_ *}-}G.00\)_ *}-}H.00\)_ *}(}N.00\)_ *}(}O.00\)_ *}(}Q.00\)_ *}-}R.00\)_ *}(}S.00\)_ *}(}T.00\)_ *}<}W.00\)_ *?;_ }(}X.00\)_ *}<}Y.00\)_ *?;_ }(}Z.00\)_ *!20% - :_寚eW[湗r 1O20% - :_寚eW[湗r 1 ef籴? %!20% - :_寚eW[湗r 2O"20% - :_寚eW[湗r 2 ef? %!20% - :_寚eW[湗r 3O&20% - :_寚eW[湗r 3 ef眄? %!20% - :_寚eW[湗r 4O*20% - :_寚eW[湗r 4 ef蛱 %!20% - :_寚eW[湗r 5O.20% - :_寚eW[湗r 5 ef蓦? %!20% - :_寚eW[湗r 6O220% - :_寚eW[湗r 6  ef怙? %!40% - :_寚eW[湗r 1O40% - :_寚eW[湗r 1 蘈雌? %!40% - :_寚eW[湗r 2O#40% - :_寚eW[湗r 2 蘈? %!40% - :_寚eW[湗r 3O'40% - :_寚eW[湗r 3 蘈圹? %!40% - :_寚eW[湗r 4O+40% - :_寚eW[湗r 4 蘈鏅 %!40% - :_寚eW[湗r 5O/40% - :_寚eW[湗r 5 蘈阶? %!40% - :_寚eW[湗r 6O340% - :_寚eW[湗r 6  蘈凄? %!60% - :_寚eW[湗r 1O 60% - :_寚eW[湗r 1 23帺? %!60% - :_寚eW[湗r 2O$60% - :_寚eW[湗r 2 23舭? %!60% - :_寚eW[湗r 3O(60% - :_寚eW[湗r 3 23缮? %!60% - :_寚eW[湗r 4O,60% - :_寚eW[湗r 4 23賔 %! 60% - :_寚eW[湗r 5O060% - :_寚eW[湗r 5 23浡? %!!60% - :_寚eW[湗r 6O460% - :_寚eW[湗r 6  23┬? %"€~vR詋 #h槝+h槝 DTj%$h槝 1=h槝 1 DTj%Dr?%h槝 2=h槝 2 DTj%?⒏?&h槝 3=h槝 3 DTj%23帺?'h槝 4/h槝 4 DTj%(頬5頬 俏 %€+8^膲 %)8^膲 2*€-厤  c?%+}Y5}Y 骑? a% ,Gl;`GGl;` %Dr?Dr?-€'^.€ '^[0] /梴o梴 蝌? 鷠% 0纇錱USCQ搹eQo搹eQ 虣 ??v% ?€ 5 騗繈顣剉厤  昈r% @鑜蕬^ 鑜蕬 ?膊?膊?膊? 膊?XTableStyleMedium2PivotStyleLight16` 渋Gl;`VV! ;g 抍廭o兞T酧o`厤魦ffN匭筟micromedex R?uTBR媁膲10齎FDA*gyb芉鍕(u誰 20 0NCCN4N奮瀃鯈cWS-邩S怢v 02019.V2  30kSeP訷邩Lv蕥梪膲2018t^Hr 鰛蔞3mg@垺{'`魎FT3-12mg/d@垺{'`魎FT€鉙g2w嵥YBR蠎3mg/錯 9hnc*NSO頬_ 髞\蟢敄2hT瀀燫o兿 錘緩0Rg'Y颯€譙BR蠎 FO蟢錯N擽厤菑12mgX1.齎FDA\*gyb芉aS鬩蒪@l(u嶯籰梪@垺{'`魎FT 2.2016-N齎@垺{'`鍂湒峹蕥梪c黐膲苺眡o憊憫b6RBR颯(u嶯籰梪{?NVaD YHY蘐P熓SaS鬩蒪@l鵞VaD€剉鍂烺齹湒峹wQ g9e刄\O(u0 3.1y?N奮xvzhf (W@垺{'`魎FT€-N aS鬩蒪@l籰梪NgbL垷R齹蔛L圍N莡秗剉{彟^9e刄鴙sQ0Moretti R, Torre P, Antonello RM, et al: Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003; 15:265-272.  Class a! a Class a! b_痵鱴p扂€?Q鍅%`'`薽鬩苸迉}v@埮u '10齎FDA*gyb芉鍕(u誰 20?Q鍅%`'`薽鬩苸迉}v@埮u蕥梪膲2018t^Hr Class a!a垟BR 15mg/10ml(u嶯寑?'`"}lxS莡ALS 剉籰梪 耂翂FDA魦ffNClass I Category AGrBR5mg010mg5-10mg/dOR薡籰梪(u蠎N錯N!k N!k5mg awMR鉙g0髞\魚cN*NgN,?-6hT  錘膵鱊閑g剉4N奮蚐擽 蔛緩0R3z`Sm0KNT颯錘\BR蠎瀀燫0RN錯N!k N!k10mg0"1. 齎FDA\*gyb芉YHY蘐P?u嶯籰梪@垺{'`魎FT 2.2016-N齎@垺{'`鍂湒峹蕥梪c黐膲苺眡o憊憫b6RBR颯(u嶯籰梪{?NVaD YHY蘐P熓SaS鬩蒪@l鵞VaD€剉鍂烺齹湒峹wQ g9e刄\O(u v^NYHY蘐P?10mg/d)颯9e刄VaD€剉L圍N莡秗孴錯8^烺齹0 3.2y?N奮xvzhf N塠paBR鴙詋 YHY蘐P燂S9e刄@垺{'`魎FT€剉鍂孴;`SO烺齹0Black S, Roman GC, Geldmacher DS, et al: Efficacy and tolerability of donepezil in vascular dementia. Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34:2323-2332. Wilkinson D, Doody R, Helme R, et al: Donepezil in vascular dementia. A randomized, placebo-controlled study. Neurology 2003; 61:479-486. 10mg 10-20mg/d7,{NhT剉BR蠎:N蟢錯5mg ,{孨hT蟢錯10mg ,{ NhT蟢錯15mg ,{踁hT_薡錘Tg(u╟P儎v魚cBR蠎蟢錯20mg1. 齎FDA\*gyb芉褢R(u嶯籰梪@垺{'`魎FT 2.2016-N齎@垺{'`鍂湒峹蕥梪c黐膲NMDA譙SO頱梑BR褢R颯9e刄{?NVaD€剉鍂烺齹湒峹 3.2y?N奮xvzhf N塠paBR鴙詋 褢R颯9e刄{?N@垺{'`魎FT€剉钀R莡秗膵R0Wilcock G, Mobius HJ, & Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychophamacol 2002; 17:297-305. Orgogozo JM, Rigaud AS, & Stoffler A: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834-1839. 閑慴6R玔)A枡!k峸兿?0mg鉙gb10mg N+Tg20R煍N!k qQ4!k0錘T9e:N蟢4^6\鰁10^20mg鉙gb N+Tg 擽(uN厤菑3)Y010齎FDA*gyb]x飩0Ws^(u嶯閑慴6R玔) 2."寈^,T[SNS,祂沵.嘫褃f[[M].,{]NHr.-N齎篘lkSu鶴Hr>y,2018:96-97u?3.-NNS;Sf[O 04N奮蕥梪cWS嘫褃R孮 0 3. 0閑剉4N奮蕥璭N籰梪cWS.2014 0 Class b!f珒U鷢50mg*7抾^y蟸匭R蘬$v l忹y'`脌/爛/饊/簚/鴢z乛y蟸匭R蘬$v 200 mg/m2/錯 蟢錯1!k qQ5)Y 蟢28)Y:NN*NhTgQ10齎FDA*gyb芉鍕(u誰 20NCCN4N奮瀃鯈cWS-^y蟸匭R蘬孴線 Nz伩€$v蕥梪cWS2019.V1  30 0-N齎脌爛饊^y蟸匭R蘬縺$vN禰qQ茓 02016t^Hr  烻裇-N^y蟸鹼邁薽鬩$vH 10齎FDA*gyb芉鍕(u誰 20 0NCCN4N奮瀃鯈cWS--N^y蟸鹼邁縺$v 02019.V1  30kSeP訷v`'`薽鬩$v蕥梪膲2015t^Hr  墊垟1mg:5ml潃線鼅T乢1-2mg/!k 12hN!kg'YBR蠎12mg/dY 仺c鑜b鬾鑜1^2mg/ !k 12h N!kY ba╟鑜髞\15min  bc韣Y 伖p鬾  g籰梪擽T{蚐擽Rc韣擽(u5^7d俌済鄀 蚐擽 1^2mg/ !k,6h N!kY ba╟鑜bc韣Y 伖p鬾  g 蚐擽Rc韣擽(u5^7d0\PoT舥臽蚐Y 颯峇蛻Y T7hBR 蠎0俌済鄀蚐擽 颯瀀燫BR蠎 g'YBR蠎12mg/d10誰齎魦ffNyb芉yr)R燫婼 }(u嶯潃線鼅T乢 202017-NNS;Sf[O潃舥f[RO 0潃lxSy?l蔛鴙sQv^裇莡剉蕥梪cWS 0 302018 0EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis 02018'k2m潃舥f[O1Y鉔P'`潃lxS4N奮蕥梪cWS 諲珒f瑐\緗_w崉vN瞼莡81.齎FDA*gyb芉鍕(u誰 2.-NNS;Sf[O7u褃f[RO.2013 -NNS;Sf[O7u褃緐舥蕥籰鹼R-7u'`N瞼莡蕥梪cWS.諲KQ珒鳶0.5mg,1mg,5mg籰梪烻裇'`線舥鼅T乢蔛黵畊'`線巔0.5mg qd|10齎FDA*gyb芉諲KQ珒鳶(u嶯籰梪線舥鼅T乢/黵畊'`線巔 20KDIGO線\t緐舥cWS 0KDIGO Clinical Practice Guideline for Glomerulonephritis 0 30RCT膵鱊Praga M et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007 May;71(9):924-30 40RCT膵鱊Bao H et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 Oct;19(10):2001-10線舥鼅T乢Class a!a 線舥鼅T乢ClassIIb 線舥鼅T乢CategoryB"}蒪^桙\0.2g 蟸 Ol?f<\孴侟\f<\孴^tb^桙\籰梪1Y%崉vZfgbl忹y'`脌爛S愻??v0.4g/bid)1.齎FDA*gyb芉鍕(u誰 2.NCCN4N奮瀃鯈cWS-o從~莮墍$v2019.V2  Class IIa Class IIb檒)R鷢25mg/Gr:_魐'` 侎g巔0鷁畫R薡BR蠎25-50mg/d n瀀燫髞 gHe0颯€譙剉gNOBR蠎魚c 8^(u蠎50-100mg/d}10齎FDA*gyb芉檒)R鷢(u嶯:_魐'` 侎g巔 20螛nMQ玼緐舥厤o兞T魦ffN(uoN禰qQ茓KN N --:_魐'` 侎g巔^Nwo僨[O2016t^12g12錯pS裇  30:_魐'` 侎g巔蕥璭蔛籰梪cWS -NNS;Sf[O螛n舥f[RO 2010. 14(8), 557-559< Category C籗(l燫婼 }0.1mgY?\莡/w嵥Y塠hQ(u蠎:N7u'`0.1mg 蟢)Y1!ksY'`0.05mg 蟢)Y1!k 颯9hnc€剉梪He宼eBR蠎0黮<\~g{|螛n'`sQ倐巔41.齎 FDA 騗yb芉黮<\~g(u嶯籰梪RA 2.螛nMQ玼緐舥({|螛nsQ倐巔) 厤o兞T魦ffN (uoN禰qQ茓鵚騠^X200mg//eY裇'`uS鈃Lv500mg/m2,蟢3hTN!kA1.齎FDA*gyb芉鵚騠^X(u嶯b篘uS鈃LvY裇剉籰梪 2.NCCN4N奮瀃鯈cWSuS鈃LvS靊搹uSLv孴烻裇'`y仠丩v2019.V1 ^)R蘐n蕬Gr&`$3mg a$6mg b$9mg 蘏T臽a湒峹亷聄裇\O%`'`g剉籰梪w嵥YBR蠎6mg/d 颯宼e髞3-12mg/d[1][2]1.齎FDA*gyb芉^)R蘐n蕬Gr(u嶯籰梪蘏鴙臽a湒峹0 2. 02018Hr燫b'Y慴翋孴&qQ喕l梪Q軂/齎E柼S鴙湒峹f[O蘏鴙湒峹tcWS 0-N ^)R蘐n懌埁cP傶N亷聄裇\O%`'`g剉N縹籰梪 愰bKNN0 3. 0-N齎蘏鴙湒峹2柣lcWS,{孨Hr  0-N ^)R蘐n?f亷聄裇\O%`'`g剉枡 惃cP僶僫rKNN+RA 00.25g/Gr 0 25 g/抾 籰梪鹼邁'`慹黵畊 1-2g/d R2!k鉙g1. 齎FDA*gyb芉Tf€Z憃慓r籰梪鹼邁'`慹黵畊0 2. 0sQ嶯pS裇螛nMQ玼緐舥{|螛nsQ倐巔0鹼邁'`慹黵畊 厤o兞T魦ffN(uoN禰qQ茓剉愬w 0^Nwo僨[O噀鯪 oO2014 48鱏 3. 2008t^EULARsQ嶯SLE籰梪╟P凒[嶯籰梪鄀蚐擽b纎 }N齹螿髞儚NO魚c蠎剉SLE€ MMF/f颯 ?u剉MQ玼慴6RBRKNN#黵畊'`線巔  b篘Class I ?Q鍅Class I*黵畊'`線巔  b篘Class a!a ?Q鍅Class a!aTf€Z憃鰛蔞250mg,GrBR500mg#10(u嶯黵畊'`線巔剉駤黐銐蔛魚c籰梪 20(u嶯烻裇'`線\t緐舥籰梪500mg qd€10齎FDA*gyb芉Tf€Z憃?u嶯籰梪黵畊'`線巔/(u嶯烻裇'`線\t緐舥籰梪 20KDIGO線\t緐舥cWS 0KDIGO Clinical Practice Guideline for Glomerulonephritis 0 30RCT膵鱊: Dooley MA et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95 40陙珟鵞gqxvz: Choi MJ et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002 Mar;61(3): 1098-114%黵畊'`線巔  b篘Class a!a ?Q鍅Class a!a#黵畊'`線巔  b篘Category A ?Q鍅Category B/l.ls^25mg緰籰'`緗^yR聢莡孴Y裇'`陙@gL圍N剉緗^yR聢莡g'Y錯BR蠎900mg[1]hFDABR蠎w嵥YBR蠎12.5mg,qd-bid 鬾歔BR蠎(W€譙凈V匭 蟢錯BR蠎瀀燫25 - 50mg $NhTT緩0R蟢錯300 - 450 mg剉顅hBR蠎;彇T剉瀀燫擽N厤菑1髞2!k 蟢hT瀀燫N厤菑100雓KQ01.齎FDA騗yb芉/l.ls^(u嶯籰梪緰籰'`緗^yR聢莡孴Y裇'`陙@gL圍N剉緗^yR聢莡剉g'Y錯BR蠎:N900mg 2.-NNS;Sf[O 0緗^yR聢莡2柣lcWS 0,S琋'Yf[;Sf[鶴Hr>y,俹侞N 3.齎FDA臢yb芉/l.ls^(u嶯緰籰'`緗^yR聢莡孴Y裇'`陙@gL圍N剉緗^yR聢莡剉籰梪 t拵N/l.ls^'YBR蠎O(u鰁No偼S擽儚YN%N蛻 4N奮 N(u嶯 N饛悢^莡鰁鷁畫蛻筽耂€魦ffNg貧BR蠎&緰籰'`緗^yR聢Class a!aY裇'`陙@gL圍N剉緗^yR聢Class a!a'緰籰'`緗^yR聢Class a!aY裇'`陙@gL圍N剉緗^yR聢莡Class a!b+緰籰'`緗^yR聢Category BY裇'`陙@gL圍N剉緗^yR聢莡Category B0.25g/Gr~10齎FDA*gyb芉骻.l鷛!TvU(u嶯:_魐'` 侎g巔 20螛nMQ玼緐舥厤o兞T魦ffN(uoN禰qQ茓KN N --:_魐'` 侎g巔^Nwo僨[O2016t^12g12錯pS裇  30:_魐'` 侎g巔蕥璭蔛籰梪cWS -NNS;Sf[O螛n舥f[RO 2010. 14(8), 557-559筓kxs^$`$25mg a$100mg b$200mg c$300mg蘏鴙湒峹慴翋鴙%`'`gUSN籰梪Z,{1錯N!k50mg N錯N!k0,{2錯 N!k100mg N錯N!k0,{3錯 N!k200mg N錯N!k0,{4錯 N!k300mg N錯N!k0o僫rawMRg(u ╟P兿k錯g'YBR蠎300mg/d01.齎FDA騗yb芉筓kxs^(u嶯b篘蘏鴙湒峹慴翋鴙%`'`gUSN籰梪0 2. 02018Hr燫b'Y慴翋孴&qQ喕l梪Q軂/齎E柼S鴙湒峹f[O蘏鴙湒峹tcWS 0-N 筓kxs^/f蘏鴙湒峹I媁慴翋g剉N縹籰梪 愰bKNN_N/f蘏鴙湒峹II媁慴翋g剉N縹籰梪 愰b0 3. 0-N齎蘏鴙湒峹2柣lcWS,{孨Hr  0-N 筓kxs^/f蘏鴙湒峹I媁慴翋裇\O%`'`g剉枡 惃cP僶僫rKNN+RA  _N/f蘏鴙湒峹II媁慴翋裇\O%`'`g剉枡 惃cP僶僫r+RA 0KQ蒪H\鑞10ML,1.齎FDA*gyb芉鍕(u誰 2.2019.V2 NCCN4N奮瀃鯈cWS%`'`託'`}v@埮u Y楄l篘MQ玼t藛}v 2.5g50mlba'`巔'`1佊殬?`Y裇'`^y蟸9h^y蟸舥CIDP B枡!k(uo傷`峸傿R蠎2g/kg,Rb2~4)Y迯韣搹鑜魚c搹瞞BR蠎1g/kg 颯N!k'`搹孾bRb2BR迯韣2)Y搹孾 蟢3hT蛻YN!k0;鷁畫枡!k搹鑜悋s:N0.01~0.02ml/kgSO蛻/R煍,鍌鄀No偼S擽颯n燫隷 g隷:N0.08ml/kgSO蛻/R煍01.齎FDA騗yb芉Y楄l篘MQ玼t藛}v(u嶯CIDP錘9e刄^y蟸寑墍媖緐孴_c$O蔛(u嶯魚c籰梪2朾kY裇0 2.Perez E E , Orange J S , Bonilla F , et al. Update on the use of immunoglobulin in human disease: A review of evidence[J]. Journal of Allergy and Clinical Immunology, 2017, 139(3):S1-S46. 3.-N齎ba'`巔'`1佊殬?`Y裇'`^y蟸9h^y蟸舥蕥梪cWS(2010)2uU[n?GrBR0.5mg, 2mg, 4mg, 10mg, 100 mg, 500 mg 鑜\BR1ml:150mg!-N'`閑焣(Central precocious puberty)4-8mg qd61.齎FDA*gyb芉鍕(u誰 2.-NNS;Sf[O 04N奮蕥梪cWS匭R蘬蔛鉔"?`緐舥Kb孮 0\2uU[n?u嶯籰梪'`閑焣0 T壷N鑞1g:1.齎FDA*gyb芉鍕(u誰 2.2019.V3 NCCN 4N奮瀃鯈cWS€侎€Lv 3. 0€侎€Lv蕥籰膲2018Hr  04 Nkx鰛蔞 25mg/抾 銐r^錻鼅T莡I{緐舥_w崉v鉙r^莡 25mg,tid"1. 0-NNS篘lqQ孴齎o儀Q4N奮(uo儃樺w2010Hr 0 2. 0齎禰Y筫茤 0 10ml:250mg;熃TLv駤黐S梪bZfgN縹籰梪J10齎FDA*gyb芉5-FU嶯;熃TLv 20NCCN4Y垬钀縺$v4N奮瀃鯈cWS2019 V1 20mg:0.5ml4Y垬钀逌Lv駤黐S梪bZfgN縹籰梪?10齎FDA騗yb芉Y壷N[Nz樎05-l?\'VvUT€T(u嶯4Y垬钀逌Lv剉駤黐S梪 20NCCN4Y垬钀縺$v4N奮瀃鯈cWS2019 V1 10ml20mgY裇bl忹y'`sNz丩vN縹USo兓l梪I1.齎FDA*gyb芉鍕o?u嶯ZfgsNz丩v 2.NCCN4N奮瀃鯈cWSsNz丩v2019.v1 3.-N齎4N奮縺$vf[OCSCO sNz丩v蕥梪cWS(2019Hr) CategoryB Y裇uS鈃LvN縹S梪D1.聰OeabY裇aS聰+?峉O? }BR蠎30mg/? 蟢4hT1!k 2.聰€oY裇?峉O? }USoBR蠎40-50mg/? 蟢4hT1!kO1.齎FDAyb芉(u嶯+T聰S梪1Y%崉vuS鈃Lv 2.NCCN4N奮瀃鯈cWSuS鈃Lv2019.V1╟P 3.Z€YN孨噾S?峉O? }籰梪uS鈃Lv剉-N齎N禰qQ茓2018t^ 0W^Xs|~g1ml/5mg (u嶯閑肙蝷簚b焣NxlfaS~gsN弫15g//e3-12g?Q鍅愊Y(u 蟢Zf1!k梪 zN厤菑1*Ng CategoryB 2500IU 3500IU 畍 N鑜\ 2500-3500IU 100mg(4ml)/鰐01.Zfg蔛Y裇P[玔縺$vN縹T€T+}Ig噾+z樎?aS聰 2.鈋€_譙菑S梪N蹚U\剉P[玔縺$v孨縹USo兓l梪 15mg/kg q21d 41.齎FDA騗蟸yb芉O鄐US梑(u嶯Y裇'`P[玔縺$v 2.NCCN4N奮瀃鯈cWSP[玔縺$v2019.V 0.1mg//e爛梙;畍 N鑜\ 蟢錯 N!k 蟢!k0.1-0.3mg 魐髞莡秗銐1.嫅x慹Y騠絸鑜\瞞刄乕錯,gHr魦ffNyb芉鍕(u誰 2.NCCN Clinical Practice Guidelines in OncologyNCCN Guidelines Palliative care 3.Role of octrotide in the management of patients with cancer 4.ZfgLv莡€Tv^爛梙;柣l梪剉N禰qQ茓孨2u蘏蛝謡?\舥剺2杇1.齎FDA*gyb芉孨2u蘏蛝(u嶯剺2栔|?\舥 2.2019t^齎ADAcWS 3.-N齎2媁謡?\舥2柣lcWS2017Hr  4.孨2u蘏蛝4N奮擽(uN禰qQ茓2018Hr  5.-N齎謡?\舥MRg4N奮r^剺N禰qQ茓2019 Y壷N[`$20mg a$80mg41.齎FDA*gyb芉Y壷N[?u嶯\苸迉簚Lv剉籰梪 2< .NCCN4N奮瀃鯈cWS\苸迉簚Lv(2019.V1)凷mf<\150mgl忹y'`^\苸迉簚LvN縹籰梪150mg qd 髞\(W蹚邩MR1\鰁b蹚邩T2\鰁g(u0j1.齎FDA騗蟸yb芉凷mf<\(u嶯l忹y'`^\苸迉簚LvN縹籰梪 2. NCCN4N奮瀃鯈cWS^\苸迉簚Lv2019.V4  3.-N齎4N奮縺$vf[OCSCO) 0烻裇'`簚Lv蕥梪cWS 02017.V1 O0W^20mg簚≧ 佖殝S5mg qd 2hT-4hTT9e:N5mg bid`1.齎FDA*gyb芉O0W^?u嶯簚≧ 佖殝S 2. 02009'k2m胈伵uf[O簚≧ 佖殝S蕥璭孴籰梪cWS 0 3.-NNS;Sf[O胈@垺{褃f[O 02010t^-N齎簚貧@垕S蕥籰cWS 0  T^?f<\0.25gEGFR亃豐€N縹梑^\苸迉簚Lv 250mg qd^1.齎FDA騗yb芉 T^?f<\(u嶯EGFR亃豐€N縹梑^\苸迉Lv 2.NCCN4N奮瀃鯈cWS^\苸迉簚Lv2019.V4 3.3.-N齎4N奮縺$vf[OCSCO) 0烻裇'`簚Lv蕥梪cWS 02018  Class a!a aS聰`$15ml:150mg a$10ml:100mg^\苸迉簚LvaS聰AUC 6 d1, 蟢21d蛻Y61.齎FDA*gyb芉aS聰(u嶯^\苸迉簚Lv剉籰梪 2.NCCN4N奮瀃鯈cWS^\苸迉簚LvcWS2019.V4)5mgba'`;朸X'`簚緐舥%`'`燫蛻 $鵞桹Ob柣l梪剉BR媁燫蛻g€颯€Q嗐Sg黮<\~g蟢錯30~40mg 迯韣5)Y1. 02019 GOLD ba'`;朸X'`簚緐舥hQt!P畫COPD蕥璭0籰梪N剺2杊QtV{eu 0 2. 04N奮蕥梪cWS|T8T舥f[R孮 0(2009Hr). 篘lkSu鶴Hr>y, -NNS;Sf[O諲緩蒪^b篘 40mg qd poe1.齎FDA騗蟸yb芉諲緩蒪^?u嶯籰梪b篘簚≧ 佖殝S 2. 02014 ACCPb篘簚≧ 佖殝So僫r籰梪cWS 0 3. 02015 ESC/ERS簚≧ 佖殝S蕥璭孴籰梪cWS 0 ?W^簚≧ 佖欯垕S5mgb20mg tid 魰敄4-6\鰁0/1.齎FDA騗yb芉?W^椈l梪b篘簚≧ 佖殝S 2. 02010t^-N齎簚貧@垕S蕥籰cWS 0  Class a!a  Class a!a  Category B  O藌f穅2ml:40mg^踠g\苸迉簚Lvwz樎?0mg/m2 d1  O藌f穅60mg/m2 d10d80d15 蟢4hT蛻Yz樎?0mg/m2 d1 T€T O藌f穅65mg/m2 d10d8 蟢3hT蛻YaS聰AUC 5 T€T O藌f穅 50mg/m2 d10d80d15 蟢29)Y蛻Y21.齎FDA*gyb芉 O藌f穅(u嶯^踠g\苸迉簚Lv 2.NCCN4N奮瀃鯈cWS\苸迉簚Lv2019.V1T€TaS聰Class a!bT€Tz樎擟lass a!a@\钀Zfgbl忹y'`剉^\苸迉簚Lv T€TaS聰\O:NN縹籰梪筫Hh\1.齎FDA騗yb芉+}Ig噾}v藛}v觺T媁 T€TaS聰(u嶯b篘NTKb/gb>e梪剉@\钀Zfgbl忹y'`^\苸迉簚Lv剉N縹籰梪 2.NCCN4N奮瀃鯈cWS^\苸迉簚Lv4N奮瀃鯈cWS2019.V4 C1.齎FDAyb芉T€TaS聰(u嶯籰梪@\钀Zfgbl忹y'`^\苸迉簚Lv剉N縹籰梪 2.NCCN4N奮瀃鯈cWS^\苸迉簚Lv2019.V2 A媁墍襨襨 }100IU NSO蓇c齎FDA騗yb芉A媁墍襨襨 }(u嶯籰梪 NSO蓇c Class IIa Category B NSO蓇c齎FDA騗yb芉A媁墍襨襨 }(u嶯籰梪 NSO蓇c渆垬莡齎FDA騗yb芉A媁墍襨襨 }(u嶯籰梪渆垬莡 烻裇'`K NYWl莡蛻  蟢K N鑜\50IU齎FDA騗yb芉A媁墍襨襨 }(u嶯籰梪烻裇'`K NYWl莡蛻 螿{彵v箏N1.齎FDA騗yb芉A媁墍襨襨 }(u嶯螿{彵v箏 2.-NNS;Sf[Oteb_Y褃f[RO甠R筟NNf[膥 0A媁墍襨襨 }(Wteb_Y褃剉4N奮擽(ucWS 0 ?査z蘐U d[靣莡鴙sQ剉f纎鵣莡秗 6-17乗?Q鍅R\t^2w嵥YBR蠎2mg/d n瀀燫髞5 mg/d 魰敄髞\1hT瀀燫5 mg/d 髞10 - 15 mg/d$齎FDA騗yb芉(u嶯籰梪6-17乗?Q鍅/R\t^剉d[靣莡-緗^y袕≧f纎鵣媁N硏xbN bx憼Tv^O(u 蘏鴙湒峹`!媁籰梪厪㏑(uo?10-15 mg/d,9hnc蚐擽颯瀀燫0R30mg/d FO30mg/d塠hQ'`\*g蹚L埬嬿N齎FDA騗yb芉\O:Nb篘蘏鴙湒峹`!媁籰梪厪㏑(uo蘏鴙湒峹`!媁亷聄b鱩T秗` 10-17乗?Q鍅R\t^52 mg/d 魚c2d,$N)Y匭燫蠎髞5 mg/d, 鐍韣瀀燫BR蠎髞10 mg/d 9hnc舥臽颯蟢)Y瀀燫5mg%齎FDA騗yb芉(u嶯籰梪10-17乗?Q鍅/R\t^蘏鴙湒峹`!媁亷聄b鱩T秗`絙≧齳韹鼅T乢 6-18乗?Q鍅R\t^€SO蛻\嶯50kg剉(uo兿2 mg/d 魚c2d,瀀燫髞5mg/d,g'YBR蠎瀀髞10mg/d FO魰敄髞\NhT SO蛻'Y嶯50kg剉(uo兿2 mg/d 魚c2d,瀀燫髞5mg/d魚c5d,,{kQ)YBR蠎瀀髞10mg/d g'YBR蠎:N20mg/d FO魰敄髞\NhT0齎FDA騗yb芉(u嶯籰梪6-18乗?Q鍅/R\t^剉絙≧齳韹鼅T乢蛻莡慴翋厪㏑(uow嵥YBR蠎2-5 mg/d ╟P傿R蠎 2-15 mg/d齎FDA騗yb芉\O:N蛻莡慴翋厪㏑(uo緗^yR聢莡 13-17乗?Q鍅R\t^:w嵥YBR蠎2mg/d $N)YT瀀燫髞5 mg/d ,{擭)Y瀀燫髞10mg/d 魚cBR蠎10mg/d g'YBR蠎30mg/d.齎FDA騗yb芉(u嶯籰梪13-17乗?Q鍅/R\t^剉緗^yR聢莡?桒S9S梘爛秐Gr100mg 剺2朠[雞MRgE鵞X[(WP[雞MRgY裇螛i枌TP[雞MRg貧qS郪 }€ (W奩 Z閑-Ng奩 Z12^16hT _薡g(u\BR蠎?桒S9S梘50-100mg  颯魚c0RU[28hT0€1..齎FDA*gyb芉?桒S9S梘(u嶯剺2朠[雞MRg 2. -NNS;Sf[O嘫褃f[O 0奩 Zg貧@垕S緐舥蕥籰cWS2015  0 3.齎嘫褃;S^f[OACOG 0奩 Zg貧@垕S蕥璭孴tcWS 0 4.齎剺2g錧\O膥USPSTF 0NOBR蠎?桒S9S梘剺2朠[雞MRg4N奮cWS 040mg匭\ N(u嶯脌_c$Obk@0/gTY裇'`坢SS慂Q@垊?貧qS€ &脌\暲h錱T藌sS賬圢峸傿R蠎80mg iv 韣錘8mg/h iv 魚c3^6)YN1.齎FDA衏蔛颯(u嶯M朜Ob篘籰梪'`匭\暲h錱T脌bAS孨c爛僴峇鶴@垊v螛i 2.-NNS;Sf[O匭褃f[O 0%`'`^梇 侐f _'` N坢SS慂Q@埵嫽lcWS2015  0 ~傴S塣憂fpQ慴翋莡蛻  12乗-17乗R\t^#w嵥YBR蠎:N10mg/d 魚cBR蠎10mg/d 3hTT颯瀀髞20mg/do1.齎騗FDAyb芉~傴S塣憂fpQ(u嶯12乗髞17乗R\t^蛻慴翋莡剉籰梪 2.-NNS;Sf[O緗^y舥f[O 0慴翋湒峹2柣lcWS 0`$5mg a$10mg&qQ喦u10mg/d NhTT颯燫髞20mg/d齎FDA騗yb芉~傴S塣憂fpQ籰梪b篘^踠'`&qQ啘枍xClass `!`$5mg a$20mg :_霃莡R薡BR蠎蔛鬾歔:鉙g10mg /d01hTT颯瀀燫髞20mg/d1.齎FDA*gyb芉(u嶯~傴S塣憂fpQ(u嶯:_霃莡 2.齎APA緗^y舥f[f[O 0Practice guideline for the Treatment of Patients With Obsessive^Compulsive Disorder 0 eY.ls^ 13-17乗R\t^3w嵥YBR蠎:N2.5-5mg/d 錘2.5-5mgE^瀀螿 顅hBR蠎:N10mg/d g'YBR蠎:N20mg/d[1.齎FDA騗yb芉eY.ls^鉙gBR媁(u嶯籰梪13-17乗?Q鍅緗^yR聢莡 2.-NNS;Sf[O緗^y;Sf[O2015 0緗^yR聢莡2柣lcWS 0S梪鴙sQUTTt1.齎FDA*gyb芉eY.ls^(u嶯S梪鴙sQ剉UTT 2.NCCN4N奮瀃鯈cWSbkUT2018.V3  3.-N齎梑LvOSOLv莡穅YN裏o`籰梪NN訷XTO0-N齎4N奮縺$vf[O梑縺$vo僫r塠hQtN禰訷XTO 0縺$v籰梪鴙sQUTT2柣lcWS( 2014 Hr) 0慴翋莡'Nl堾lT€T籰梪蛻莡慴翋莡鰁w嵥YBR蠎5mg qn 颯宼e髞5-20mg qn7齎FDA騗yb芉eY.ls^鉙gBR媁Nl堾lT€T(u嶯籰梪b篘蘏鴙I媁慴翋莡0蛻慴翋莡 eY檒)R聰50mg觺爛Lv 厪㏑'`IIg N5-l?\'VvU/歂鯯x懩~TF1.齎FDA*gyb芉eY檒)R聰(u嶯N5-l?\'VvU/歂鯯x慣€T厪㏑籰梪b篘IIg觺爛Lv 2.NCCN4N奮瀃鯈cWS觺魐爛Lv[{錱2018.V1  邩Lv0脌Lv0觺魐爛Lv剉厪㏑S梪 苺S恦`'`縺$v蔛薽鬩$v剉孨縹籰梪1.FDA騗yb芉eY檒)R聰(u嶯 IIIg觺爛Lv剉厪㏑籰梪 2.NCCN4N奮瀃鯈cWS脌Lv2019.V1  3.NCCN4N奮瀃鯈cWS邩S怢v孴脌邩LuYLv2019.V1  4.NCCN4N奮瀃鯈cWS潃苺縺$v2019.V2  5.NCCN4N奮瀃鯈cWS魐爛Lv2019.V2 K邩Lv Class a!a 脌Lv Class a!a 觺魐爛Lv厪㏑S梪Class a!a 苺S恦`'`縺$v Class a!a 薽鬩$v Class a!aK邩Lv Class a!b 脌Lv Class a!a 觺魐爛Lv厪㏑S梪Class a!b 苺S恦`'`縺$v Class a!b 薽鬩$v Class a!bT邩Lv C< ategory B 脌Lv Category B 觺魐爛Lv厪㏑S梪Category B 苺S恦`'`縺$vCategory B 薽鬩$v Category B鬩)RfUS梑 潃鹹i梑抍蚐擽剉剺220mg iv /gMR2h蔛/gT,{踁)YN1.齎FDA*gyb芉鬩)RfUS梑(u嶯剺2b篘潃鹹i抍蚐擽 2.2015'k2m潃xvzf[O4N奮瀃鯈cWS潃鹹i 3.2018ALTN4N奮cWS潃鹹i-N剉MQ玼慴6RO鄐US梑`$100mg:4ml a$400mg:16ml鐍裇嶯t^劅鴙sQ'`臑慹豐'`剉 佨~渷癳u@垺{S籹僼SO匭鑜\1.25mg/0.05ml鑜\瞞 `$100mg:4ml a$400mg:16ml l忹y'`線Lv *蘏hT筫Hh10mg/kg NhT筫Hh7.5mg/kg q1.齎FDA騗yb芉O鄐US梑(u嶯籰梪l忹y'`線Lv 2.2016齎縺$vMQ玼籰梪f[OqQ茓餢fMQ玼梪誰籰梪線苸迉Lv 3.2018齎E€t^縺$vf[Oa翂fN€t^l忹y'`線苸迉Lv€剉t 4.NCCN4N奮瀃鯈cWS線Lv2019V4 l忹y'`sNz丩v&T€T+}Ig噾S梪筫Hh鰁Y 佽l\剉╟P傿R蠎10 mg/kg 蟢2hT賬o?!k0 91.齎FDA*gyb芉O鄐US梑\O:NT€To僫r籰梪b篘l忹y'`sNz丩v 2.NCCN4N奮瀃鯈cWSsNz丩v2019.V1  聰€o儖WY裇uS鈃Lv1.Y 亾忚l 10mg/kg 蟢$NhT賬oN!k0T€T+}Ig噾0Y詆詋f?峉ObXb蔿f穅蟢hT賬oN!k -N剉鸑aN蛓 2.Y 亾忚l 15mg/kg 蟢3hT賬oN!k0T€TXb蔿f穅蟢3hT賬oN!k  w1.齎FDA騗yb芉O鄐US梑T€T+}Ig噾0Y詆詋f?峉ObXb蔿f穅-N剉鸑aN蛓(u嶯籰梪b篘KNMR譙菑N厤菑2gS梪剉聰€o儖WY裇uS鈃Lv0搹uSLvb烻裇'`y仠丩v 2.NCCN4N奮瀃鯈cWSuS鈃LvS靊搹uSLv孴烻裇'`y仠丩v 2019.V1  Y裇bl忹y'`玔垬Lv,15mg/kg Y 亾忚l 蟢3hT賬o?!k0T€T+}Ig噾孴z樎b+}Ig噾孴Xb蔿f穅-N剉鸑aN蛓1.齎FDA騗yb芉O鄐US梑T€T+}Ig噾孴z樎bT€T+}Ig噾孴Xb蔿f穅(u嶯籰梪b篘cEN'`0Y裇bl忹y'`玔垬Lv 2.NCCN4N奮瀃鯈cWS玔垬Lv2019 V3  0.1guS鈃 N畍LvC1.齎FDA騗yb芉O鄐US梑(u嶯籰梪b篘uS鈃 N畍Lv 2.NCCN4N奮瀃鯈cWSuS鈃Lv2018.v2 !T300mg  @\钀Zfg N颯Rdbl忹y'`剉饊z丩v T€T T壷N鑞\O:NN縹籰梪筫HhC100mg 鉙g qd zzyg(u髞\(W蹚邩MR1\鰁b蹚邩T2\鰁g(u 0c韣(uo凈v0R緐舥蹚U\b鶴皊N齹€譙剉襨'`蚐擽0T€T T壷N鑞0G1.齎FDA騗yb芉凷mf<\T€T T壷N鑞(u嶯b篘@\钀Zfg0N颯Rdbl忹y'`饊z丩v剉N縹籰梪 2.NCCN4N奮瀃鯈cWS饊z丩v2019.V2 500mgY蔞uS鈃鼅T乢 1.5g/d R3!kg(u1.齎FDA*gyb芉衯x憣N2u蘏蛝(u嶯籰梪b篘Y蔞uS鈃鼅T莡 2. 02013ENDO齎Y蔞uS鈃鼅T乢剉蕥梪cWS 0 3.-NNS;Sf[O嘫褃f[O 04N奮蕥梪cWS嘫褃R孮 0 4. 02012 ESHER/ASERqQ茓Y蔞uS鈃鼅T乢PCOS 鵞sY'`eP穅剉q_蚑 0l?\'VvU 10ml:0.25g4Y垬钀逌LvhQ珟S梪蔛厪㏑S梪s1.齎FDA*gyb芉l?\'VvU(u嶯4Y垬钀逌LvhQ珟S梪蔛厪㏑S梪0 2. NCCN4N奮瀃鯈cWS4Y垬縺$vcWS2015.V1.0  l堾lRceGr蟸MR&qQ啘枍x120mg/)Y 迯韣籰梪b魰Gk'`籰梪g蟸MR14)Y_薡迯韣g(u髞g蟸g,{N)Y  g'YBR蠎80mg/)Y$齎FDA騗蟸yb芉l堾lGr(u嶯蟸MR&qQ啘枍x0臢P枎NSARAFEMGrBR 蔪P`湒峹6w嵥YBR蠎10mg/d,魚cNhT 瀀燫髞20mg/d 鍌舥臽6RNt骮 颯鐍韣瀀燫 g'YBR蠎N厤菑60mg/d齎FDA騗蟸yb芉l堾l(u嶯:_蔪P`湒峹剉籰梪 7乗錘 N?Q鍅R\t^Dw嵥YBR蠎:N10mg/d,魚c2hT 魚cBR蠎:SO蛻儚{弰v?Q鍅20mg/d-30 mg/dR\t^蔛SO蛻儚蛻?Q鍅20mg/d-60 mg/d齎FDA騗蟸yb芉l堾l(u嶯7乗錘 N?Q鍅:_霃莡剉籰梪S N噾0.25ug2u秗羍z仧R齹螿惽u_w崉vNO檾@埱u痵b[ }鹼邁'`慹黵畊1.齎FDA*gyb芉痵b[ }(u嶯籰梪鹼邁'`慹黵畊 2.-NNS;Sf[O螛n舥f[RO 0鹼邁'`慹黵畊蕥璭蔛籰梪cWS 0 3.駛齎螛n舥f[O 02017BSRb篘鹼邁'`慹黵畊剉tcWS 0 4.-NNS;Sf[O螛nf[RO 04N奮蕥梪cWS螛n舥R孮 0r^錻鼅T乢1.齎FDA*gyb芉痵b[ }(u嶯籰梪r^錻鼅T乢 2.-NNS;Sf[O螛n舥f[RO 0r^錻鼅T乢蕥璭蔛籰梪cWS 0 3.駛齎螛n舥f[O 02017BSRb篘烻裇'`r^錻鼅T乢剉tcWS 0鰛蔞 25mg 蛻僴'`觺爛巔1.齎FDA*gyb芉痵b[ }(u嶯籰梪僴'`觺爛巔 2.-NNS;Sf[O坢S舥f[O 0巔莡'`爛舥蕥璭N籰梪剉qQ茓a翂 0 3.'k2mKQWi`舥孴觺爛巔膥莮 02017ECCO僴'`觺爛巔猒翄qQ茓 0痵鱴p扂€<  墊垟200mgc1.齎FDA*gyb芉痵鱴p扂€(u嶯籰梪鹼邁'`慹黵畊 2.-NNS;Sf[O螛n舥f[O 0鹼邁'`慹黵畊蕥璭蔛籰梪cWS 0 鏃500mg NW0W檒fWo8mg胈汻p堩z(NYHA II髞iv \@Rpe40%b錘 N),w嵥YBR蠎:N4mg qd,9hnc€€譙 z 'Y敄$NhT颯BR蠎燫P 顅hBR蠎:N32mg qdD1.齎FDA騗yb芉NW0W檒fWo?u嶯籰梪b篘胈汻p堩z 2. 0-NNS胈@垺{舥Bg譥 02018,46(10) 0-N齎胈汻p堩z蕥璭孴籰梪cWS2018 0/`$25mg a$100mg b$200mg c$300mgN硏xbN bx憼Tv^O(u 蘏鴙湒峹魚cg籰梪厪㏑(uo?魚c錯BR蠎:N400-800mg/d R$N!kg(u g'Y錯BR蠎:N800mg/d0-齎FDA騗yb芉筓kxs^(u嶯籰梪b篘N硏xbN bx憼Tv^O(u 蘏鴙湒峹魚cg籰梪厪㏑(uo 0`$25mg a$100mg b$200mg c$300mg 蘏鴙湒峹`!媁亷聄鴙%`'`g 10-17乗R\t^@400-600mg/d R$N!k髞 N!kg(uw嵥YBR蠎:N25 mg/d 蟢錯g'Y瀀燫BR蠎d"100mg g貧賬o傿R蠎:N600mg/d0&齎FDA騗yb芉筓kxs^(u嶯籰梪R\t^10-17乗 蘏鴙湒峹`!媁亷聄鴙%`'`g-`$25mg a$100mg b$200mg c$300mg%齎FDA騗yb芉筓kxs^(u嶯籰梪R\t^13-17乗 緗^yR聢莡^楐~cg A,{N)YZf NBR蠎:N50mg/d ,{ N)YZf NBR蠎瀀燫:N150mg/d ╟P傿R蠎凈V150-300mg/d g'YBR蠎:N300 mg/d0齎FDA騗yb芉筓kxs^(u嶯籰梪b篘蛻莡慴翋厪㏑(uo蒪珒 N闡%`$25mg a$50mg b$100mg 蘏鴙湒峹`!媁T(uN bx憚v€籰梪剉MR2hT25mg qod KNT2hT25mg/d ,{擭hT50mg/d ,{mQhT瀀髞顅hBR蠎100mg/d0 NNv戱孅[BR蔛N bx慣€(u剉€籰梪剉MR2hT25mg/d KNT2hT50mg/d ,{擭hT100mg/d ,{mQhT瀀髞顅hBR蠎200mg/d0 Nv戱孅[BRT€(uN燫N bx 剉€籰梪剉MR2hT50mg/d KNT2hT100mg/d ,{擭hT200mg/d ,{mQhT300mg/d ,{NhT瀀髞顅hBR蠎400mg/d0BR蠎e"100mg/d R$N!kg(u0齎FDA騗蟸yb芉蒪珒 N闡(u嶯籰梪蘏鴙湒峹I媁 eg騠U2.5mgP[玔匭渷_MO莡蔛Y蔞uS鈃鼅T莡剉肙抍uS籰梪(Wg蟸觺_g3-5)Y_薡O(u BR蠎:N蟢)Y2.5-5mg 迯(u5)YC1.齎FDA*gyb芉eg騠U(u嶯b篘籰梪P[玔匭渷_MO莡蔛Y蔞uS鈃鼅T莡剉肙抍uS 2.-NNS;Sf[O 04N奮蕥梪cWS厪㏑u杒€b/gN緗P[揯R孮 0鳀鄐US梑謡?\舥'`臑慹4l縺 齎FDA騗yb芉鳀鄐US梑(u嶯籰梪謡?\舥'`臑慹4l縺 Y h^X_w崉v臑慹4l縺籹僼SO鑜\0.5mg 蟢gN!k齎FDA騗yb芉鳀鄐US梑(u嶯籰梪Y h^X_w崉v臑慹4l縺&褟茐'` 佨~渷癳u@垺{ 齎FDA騗yb芉鳀鄐US梑(u嶯籰梪褟茐'` 佨~渷癳u@垺{ 謡?\舥'`茐Q渷舥豐齎FDA騗yb芉鳀鄐US梑(u嶯籰梪謡?\舥'`茐Q渷舥豐)R蒪仠絸3mL18mgUw嵥YBR蠎:N蟢)Y0.6 mg0髞\1hTT BR蠎擽瀀燫髞1.2 mg09hnc4N奮擽T{臽礠 :N哊蹚Nek9e刄籰梪He済 蟢hT宼eN!kBR蠎 n宼e髞1.8mg02.4mg03.0mg1. 齎FDA騗yb芉)R蒪仠絸(u嶯籰梪BMI>27 kg/m2 Tv^髞\Ny槬€謤v^裇莡剉€俌貧@垕S02媁謡?\舥0貧@ b€BMI>30kg/m2剉US瘇'`謤€ 2. 齎匭R蘬f[O 02018TES褃f[餢f謤t褃f[ 0 3. 齎4N奮匭R蘬;S^f[O(AACE) 02018AACE/ACEqQ茓餢f2媁謡?\舥鼅Tt筫Hh 0 Class a!a )R鵚n`$GrBR a$鉙g瞞`$2mg a$30mg:30ml13乗蔛錘 N?Q鍅@R\t^w嵥YBR蠎0.5mg/d, 24hT蟢)Y颯瀀燫0.5b1mg 俌€譙颯瀀髞顅hBR蠎3mg/d  gHeBR蠎凈V:N1-6mg/d Q1.齎FDA騗yb芉)R鵚n?u嶯13乗蔛錘 N?Q鍅緗^yR聢莡剉籰梪 2.-NNS;Sf[O緗^y舥f[O 0緗^yR聢莡2柣lcWS 0 ?Q鍅Class a!a ?Q鍅Class a!b ?Q鍅Category B `$GrBR a$鉙g瞞`$2mg a$30ml30mg 5乗錘 N?Q鍅R\t^SO蛻20kg w嵥YBR蠎:N0.25mg/d 髞\4)YTBR蠎颯瀀髞0.5mg/d 魚cdkBR蠎 髞\14d 鍌梪HeNsO颯n燫蠎 宼eBR蠎魰敄髞\:N2hT 蟢!k瀀燫0.25mg/d0 SO蛻e"20kg w嵥YBR蠎:N0.5mg/d 髞\4)YTBR蠎颯瀀髞1mg/d 魚cdkBR蠎髞\14d 鍌梪HeNsO颯鐍韣宼eBR蠎 蟢!k 魰敄N\嶯2hT 蟢!k瀀燫0.5mg/d0 gHeBR蠎凈V:N0.5-3mg/d 颯N錯N!k賬ob\蟢錯BR蠎GWR:N$N!kg(u0顅MR\鄀SO蛻15kg剉?Q鍅€剉BR蠎penc0齎FDA騗yb芉)R鵚n懟l梪5乗錘 N?Q鍅R\t^d[靣莡-f纎鵣媁 10乗錘 N?Q鍅R\t^P?Q鍅w嵥YBR蠎:N0.5mg/d hfwbZf N鉙g 宼eBR蠎N\嶯24\鰁 瀀燫BR蠎:N0.5-1.0mg/d 顅hBR蠎:N1-2.5mg/d0 gHeBR蠎:N1-6mg/d 齎FDA騗yb芉)R鵚n懟l梪10乗錘 N?Q鍅R\t^蘏鴙湒峹`!媁)RfUS梑ba'`鹹iir梑縖;N舥 1.齎FDA*gyb芉)RfUS梑(u嶯ba'`鹹iir梑縖;N舥 2.@埐mf[h芉訷XTO/駛齎@埐mN託鹹if[O 02012 BCSH/BSBMTcWS:ba'`鹹iir梑縖;N舥剉蕥璭孴t 0 `$10ml:100mg a$50ml:500mg @h'`@\g螿\'`+}\vt1.齎FDA*gyb芉)RfUS梑籰梪b篘@h'`@\g螿\'`+}\v <  2.-NNS;Sf[O@埐mf[RO 0 @h'`@\g螿\'`+}\v蕥璭N籰梪-N齎N禰qQ茓2012t^Hr  0`$10ml:100mg a$50ml:500mg ba'`薽鬩苸迉'`}v@埮u T€Tl緩蒪鑞孴痵鱴p扂€[1.齎FDA騗yb芉)RfUS梑T€Tl緩蒪鑞孴痵鱴p扂€(u嶯籰梪b篘鈋€_*g蟸籰梪剉孴鈋€_蟸籰梪剉CD203?`ba'`薽鬩苸迉}v@埮u 2.-N齎ba'`薽鬩苸迉}v@埮u剉蕥璭N籰梪cWS(2011t^Hr) 緰籰'`蛻莡鹼邁'`慹黵畊p1.齎FDA*gyb芉)RfUS梑(u嶯籰梪N齹€譙MQ玼慴6RBR籰梪b籰梪He済 ksO剉b篘鹼邁'`慹黵畊 2.-NNS;Sf[O螛n舥f[O 0鹼邁'`慹黵畊蕥璭蔛籰梪cWS 0 3.^Nwo僨[O 0螛nMQ玼緐舥鹼邁'`慹黵畊 厤魦ffN(uoN禰qQ茓 0 Class a!b 6,{N梪 z圢Y 亾忚l500-1000mg/!k 0hT孴2 hTT1!k9hnc舥臽颯(W6-12 *NgT譙,{孨*N梪 z0z1.齎FDA騗yb芉)RfUS梑(u嶯籰梪鵞N蛓bY蛓TNF頱梑BR梪He ksO剉b篘-N蛻{|螛n'`sQ倐巔,NMTXT€T籰梪 2.-NNS;Sf[O螛nf[RO 0{|螛nsQ倐巔蕥璭蔛籰梪cWS 0 3.^Nwo僨[O 0螛nMQ玼緐舥{|螛n'`sQ倐巔 厤魦ffN(uoN禰qQ茓 0Q1.齎FDA騗yb芉)RfUS梑N謡畍(嵗o }T€T(u嶯籰梪b篘鏃f甠\ NY@垺{巔C1.齎FDA騗yb芉N謡畍(嵗o }T€T(u嶯籰梪b篘>f甠\ NY@垺{巔 2.-NNS;Sf[O螛n舥f[RO 0>f甠\ NY@垺{巔蕥璭蔛籰梪cWS 02011kx鉔kxx憼 320mg 640mg$\O:N^梱r_'`梑巔o (u嶯畍巔0n箄0h兓灩u0o僫r'`畍巔 oR鰯Q\舥剉籰梪0-4N(uMR (ump虄鑜\(u4l秐銐b5%秐瞞T擽(u0 8^(u蠎寑匭bY 佽l\N!k0.5-1g0 q1. 0謡畍(嵗o }{|o僫r4N奮擽(uc黐烻R 02011 2.-N齎-N堺S觺Tf[O畍'`舥NN訷XTO痵僗NL€N'`畍舥f[膥 0-N堺S觺T鹼邁o僫r籰梪n箄畍巔{|畍舥N禰qQ茓2015Hr  0 3.-NNS;Sf[O 04N奮蕥梪cWS畍舥N'`舥R孮 0kxU VdT巔莡'`爛舥'Y≧ 亷pT1.齎FDA*gyb芉kxU VdT(u嶯籰梪'Y≧ 亷p 2.-NNS;Sf[O螛n舥f[RO 0'Y≧ 亷p蕥璭蔛籰梪cWS 02011WSO蛻<51kgw嵥YBR蠎3mg qd 魚cBR蠎3-6mg/d SO蛻>51kgw嵥YBR蠎3mg qd 魚cBR蠎3-12mg/d!齎FDA騗蟸yb芉衯x^W堾l(u嶯籰梪12-17乗R\t^緗^yR聢莡^W堾l^踠'`&qQ啘枍x20mg/d齎FDA騗蟸yb芉衯x^W堾l(u嶯^踠'`&qQ啘枍x Class I R$OT擽纎湒峹齎FDA騗蟸yb芉衯x^W堾l(u嶯R$OT擽纎湒峹|xfPOs|3.5mgY裇'`託$v ?1.齎FDA騗yb芉|xfPOs|(u嶯Y裇'`託$v 2.NCCN4N奮瀃鯈cWSY裇'`託$v2018.v4R籰WY苸迉薽鬩$vV1.齎FDA騗yb芉|xfPOs|T€TY ?RfUS梑0痵鱴p扂€0? }孴鉙g黮<\~g(u嶯籰梪b篘鈋€_*g蟸籰梪剉WY苸迉薽鬩$v 2.NCCN4N奮瀃鯈cWS ^桮Y褢薽鬩$v2018.V2nfaS臺)R7u'`縊貀7u'`2mg qd1.'k2mEMA騗yb芉%t纒x憂faS臺)R(u嶯7u'`縊貀 2. Dig Dis Sci 2016;61(8):2357-72. 3.Am J Gastroenterol 2015;110(5):741-8. nfm\tZ|^?Q@垺{$v\嶯N乗[5hT-5g劅 R薡BR蠎0.6mg/kg qd,魰敄髞\9\鰁 R$N!k鉙gNhT鰁 宼e:N1.1mg/kg qd R$N!k鉙g;魚cBR蠎1.7mg/kg/day R$N!k鉙g c韣6*Ng0<1.齎FDA騗yb芉nfm\(u嶯籰梪?Q鍅\嶯1乗 @垺{$v 2. 0鉙gnfm\籰梪tZ|^?Q@垺{$v-N齎N禰qQ茓 02016 nf^t鬩梘75mg謡?\舥hT鬡^y蟸舥豐 ^y蟸舥t'`紆踰w嵥YBR蠎50mg tidg'YBR蠎颯瀀髞100mg tidCre"60mL/min  FO梪 z6R(WNhT匭0g(u,g罷300mg/錯 2髞4hTT紆踰*g梍0REQR銐剉€ 俌颯€譙,g罷 颯瀀髞蟢!k300 mg 蟢錯2!k b蟢!k200mg 蟢錯3!k600mg/錯 線烺齹螿悾`€ cgq魦ffN宼eBR蠎r1.齎FDA騗yb芉nf^t鬩梘(u嶯籰梪b篘謡?\舥hT鬡^y蟸舥豐 2.'k2m^y蟸舥T€遶 02010 NICE ^y蟸舥t'`紆踰o僫r籰梪cWS 0 3. 0^y蟸舥t'`紆踰蕥梪N禰qQ茓 02013 P熒b塶?`$20mg a$40mg b$60mg c$80mg)w嵥YBR蠎40mg bid N Tg 颯9hnc梪HeN€譙'`宼e:N40-80mg bid"齎FDA騗yb芉衯x慞熒b塶?u嶯籰梪b篘蘏鴙湒峹`!媁亷聄b鱩T秗` N硏xbN bx憼Tv^O(u 蘏鴙湒峹厪㏑(uo40-80mg bid N曅vbN bxT(u&齎FDA騗yb芉衯x慞熒b塶?u嶯b篘蘏鴙湒峹剉厪㏑籰梪N曅vbN bxT(u 鹼邁'`慹黵畊(u嶯{弸W  50-100 mg/dN1.齎FDA*gyb芉檒)R鷢(u嶯籰梪b篘慹黵畊 2.-NNS;Sf[O 04N奮蕥梪cWS畍舥N'`舥R孮 0 3.-NNS;Sf[O螛nf[RO 0鹼邁'`慹黵畊蕥璭蔛籰梪cWS 025mg }v^X舥蟢!k25-50mg 蟢錯3!k.1.齎FDA*gyb芉檒)R鷢(u嶯籰梪}v^X舥 2.-NNS;Sf[O螛nf[RO 0}v^X舥蕥璭N籰梪cWS 0Y裇'`託$vN!k25^50mg 蟢錯100-200mg 1.齎FDA騗yb芉檒)R鷢N0W^Xs|~gT€T籰梪癳蕥璭剉b篘Y裇'`託$v 2.NCCN4N奮瀃鯈cWSY裇'`託$v4N奮瀃鯈cWS2019.V2  3.-N齎;S^OSO@埐m褃;S^RO0-NNS;Sf[O@埐mf[RO0-N齎;S^OSOY裇'`< 託$vNN訷XTO 0-N齎Y裇'`託$v蕥籰cWS2017t^頞  0癳蕥璭剉Y裇'`託$v N0W^Xs|~gT€TH200mg/d awMRbZfT1h N0W^Xs|~gT€T籰梪28)Y :NN梪 z00W^Xs|~gBR蠎:N40mg/d R+R(W,{1-4,9-12, 17-20)Yg(u01.齎FDA騗yb芉檒)R鷢N0W^Xs|~gT€T籰梪癳蕥璭剉b篘Y裇'`託$v 2.NCCN4N奮瀃鯈cWSY裇'`託$v4N奮瀃鯈cWS2019.V2 3.-N齎;S^OSO@埐m褃;S^RO0-NNS;Sf[O@埐mf[RO0-N齎;S^OSOY裇'`託$vNN訷XTO 0-N齎Y裇'`託$v蕥籰cWS2017t^頞  0 4. 0匭褃f[ 0,{]NHr ,篘lkSu鶴Hr>y,[凣W鈒0恄8leP0媠皬;N傭f梘6乗b錘 NM6-12乗w嵥YBR蠎擽:N25 mg 蟢錯N!k13-17乗w嵥YBR蠎擽:N50 mg 蟢錯N!k0颯9hnc梪He孴€譙'`瀀燫BR蠎 蟢hT宼eN!k g'YBR蠎200mg/d1.齎FDA騗yb芉傭f梘(u嶯6乗錘 N?Q鍅:_霃莡 2.齎緗^y舥f[OAPA 0Practice guideline for the Treatment of Patients With Obsessive^Compulsive Disorder 02007Gw嵥YBR蠎:N25mg qd 閑 NbZf Ng(u g(uNhTNhTT BR蠎瀀燫髞50mg/d dkTBR蠎宼e鰁魰魰敄N擽韜嶯NhT0g'YBR蠎200mg/d0齎FDA騗yb芉傭f梘(u嶯籰梪b篘R$OT擽纎湒峹蟸MR&qQ喦u迯韣賬ow嵥YBR蠎50mg qd (Wte*Ng蟸g剉閑 NbZf Ng(u0鍌梪HeNsO BR蠎颯蟢*Ng蟸hTg瀀燫50mg/d 魐髞g'YBR蠎:N150mg/d 臑SOg賬ow嵥YBR蠎50mg qd (Wte*N臑SOg剉閑 NbZf N賬o0鍌梪HeNsO 颯(W蟢N*N癳臑SOg剉MR3)YHQ賬圢50mg/d T瀀燫髞100mg/d0齎FDA騗yb芉傭f梘(u嶯籰梪b篘蟸MR&qQ喦u Class II a>yP``莡Gw嵥YBR蠎:N25mg qd 閑 NbZf Ng(u g(uNhT0NhTT BR蠎瀀燫髞50mg/d dkTBR蠎宼e鰁魰魰敄N擽韜嶯NhT0g'YBR蠎200mg/d0齎FDA騗yb芉傭f梘(u嶯籰梪b篘>yP``莡閑膌;25-200mg/)Yb50mg/'`MR4-8\鰁 micro50mg qd 鍌8hTTHe済NsO 颯瀀燫髞100mg/dW1.齎FDA*gyb芉傭f梘(u嶯閑膌 2. 0NW\-僱\繬蘬?\Y褃f[ 0 S琋'Yf[;Sf[鶴Hr>y 韾擽剏 hT)R;N褘 3.2017 EAUcWS肦w崯R齹湒峹 閑膌 4?_騠孴_8^肦w6乗錘 N?Q鍅 50-200mg/d 齎FDA*gyb芉傭f梘(u嶯?Q鍅慴翋莡 ?Q鍅Class a!b 焇y蟸u曕VP[18ug 癳u?Q錘蔛閑?Q:@圍'l'`伵u0hT鬡^y蟸舥豐蟢!k1/e (u2ml鑜\(u4l秐銐T寑墍鑜\ qd 4hT:NN梪 zfW"}W洀搹?\觺體0.4mg,qd:1.齎FDA*gyb芉fW"}W洀(u嶯籰梪搹?\觺體 2.-NNS;Sf[O蘬?\Y褃f[RO 0-N齎蘬?\Y褃緐舥蕥璭籰梪cWS 02014yr藌^絸2.4ml(崗u~g 20g qd 畍 N鑜\齎FDA騗yb芉yr藌^絸颯(u嶯7u'`(崗u~gf詋+Y歔600mgba'`YN媁舥襨'`潃巔 鬡g O璬剺2U[嘫,,g罷籰梪ba'`YN媁潃巔剉╟P傿R蠎:N600mg 蟢)YN!k 鉙g 橫RbTGW颯 N譙蹚邩q_蚑w1.齎FDA*gyb芉f詋+Y歔(u嶯貧舥襨}徬憚vHBsAg3?`U[嘫 2. 0ba'`YN媁潃巔2柣lcWS(2015鬴癳Hr) 0 3.齎潃舥f[O 0AASLD Guidelines for Treatment of Chronic Hepatitis B 0f TeY20mg 苺S怢vN,偱`礠 N 9hncSOh坆楋y砆歔b篘剉枡!kBR蠎0 SOh坆楋y?  枡!kBR蠎 cf燫l  1.25 蟢!k40mg e"1.25-1.5 蟢!k50mg e"1.5 蟢!k60mg (u誰:N蟢錯2!k0閑ZfT鉙g 迯韣賬o?8)Y Oo`14)Y :NN*N籰梪hTg0颯9hnc€臽礠瀀螿賬o兿0蟢!k賬o兿 c40mg050mg060mg075mg踁*NBR蠎I{z槒^悶Xb愊Q0 NP曻N75mg/!k  NP曻N40mg/!k0+1.錯,gPMDA騗yb芉f TeY(u嶯籰梪b篘苺S怢v 2. 0苺Lv蕥璭N籰梪-Y褃N禰qQ茓 0micromedex *g6eU_ l忹y'`v`'`褳r }$v'蟢N梪 z28)Y0蟢錯鉙g200 mg/? (W28)Y:NN籰梪hTg匭迯韣g(u5)Y061.齎FDA*gyb芉f珒U鷢(u嶯籰梪b篘l忹y'`v`'`褳r }$v 2.NCCN4N奮瀃鯈cWS褳r }$v2018.V3N銼 }緰◤環秗絺迉Fg虄鴙sQ'`y侞lHb篘125mg,q6h,鉙g 魚c10)Y ?Q鍅40 mg/kg/day 鉙g R N0R踁!kN)Y 魚c70R10)Y g'YBR蠎蟢錯2g/1.齎FDA騗yb芉N銼 }(u嶯籰梪b篘孴?Q鍅緰◤環秗絺迉Fg虄鴙sQ'`y侞l(闟AQ笅鉙g  b篘Class `! ?Q鍅Class `! b篘Class a!a ?Q鍅Class a!a b篘Category B ?Q鍅Category B 噀蒪誰洀 `$150mg a$75mgb篘蔪P`湒峹 4O gbN4O g^:WP`鏯莡)37.5 mg/d 魚cNhT. NhTT颯瀀髞75 mg/d g'YBR蠎225mg/d!齎FDA騗蟸yb芉噀蒪誰洀(u嶯b篘蔪P`湒峹 4O gbN4O g^:WP`鏯莡b篘>yP`鏯莡 75mg/d10齎FDA騗蟸yb芉噀蒪誰洀(u嶯b篘>yP`鏯莡  Class I  Class a!a Category B LN鳶諲N10NUOKQ鶴@?`OKQ0苸虄'`OKQ0Y$O'`OKQ0鏿$O'`OKQ a(Wb篘-N 100,000*NUSMO秐銐(W500雓GS搹瞞-NN!k Y 亾忚l蟢)Y1髞3!k 蟢!k1髞2\鰁 b100,000USMO秐銐嶯2雓GS搹瞞N!k 蟢)YbaY 佽l\1髞3!k0颯9hnct^劅 莡秗怱_0W瀀螿 0=1.錯,g魦ffN 2.-N齎%N蛻佉k莡/佉k'`OKQ籰梪cWS2014  3.%`'`猒痵p堩z-N齎%`蕥4N奮瀃鯈N禰qQ茓2016 佉k莡 20N q12h 1.-N齎%N蛻佉k莡/佉k'`OKQ籰梪cWS2014  2.Karnad DR1, Bhadade R, Verma PK et al.Intravenous administration of ulinastatin humanurinary trypsin inhibitor in severe sepsisa multicenter randomized controlled study.Intensive Care Med DO I 10.1007/s00134-014-3278-8塣憂fpQ1.齎FDA*gyb芉(u嶯~傴S塣憂fpQb塣憂fpQ(u嶯:_霃莡 2.齎APA緗^y舥f[f[O 0PRACTICE GUIDELINE FOR THE Treatment of Patients With Obsessive-Compulsive Disorder 0 b篘Class a!a ?Q鍅Class a!a b篘Class a!b ?Q鍅Class a!b 墺YfUS梑 100mg:20ml@\钀Zfg4Y垬钀逌秗苸迉Lv T€T>e梪1.齎FDA騗yb芉墺YfUS梑T€T>e梪(u嶯b篘@\钀Zfg4Y垬钀逌秗苸迉Lv剉R薡籰梪 2.NCCN4N奮瀃鯈cWS4Y垬钀Lv4N奮瀃鯈cWS2018.V2 "錘聰{|o僫r:N鶺@x剉S梪1Y%T剉Y裇bl忹y'`4Y垬钀逌秗苸迉Lv USo兓l梪1.齎FDA騗yb芉墺YfUS梑US(u嶯籰梪b篘錘聰{|o僫r:N鶺@x剉S梪1Y%T剉Y裇bl忹y'`4Y垬钀逌秗苸迉Lv 2.NCCN4N奮瀃鯈cWS4Y垬钀Lv4N奮瀃鯈cWS 2018.V2 +@\钀Y裇bl忹y'`4Y垬钀逌秗苸迉Lv T€T錘聰{|o僫r:N鶺@x剉S梪孴5-FU\O:NN縹籰梪筫Hh1.齎FDA騗yb芉墺YfUS梑T€T錘聰{|o僫r:N鶺@x剉S梪孴5-FU(u嶯b篘@\钀Y裇bl忹y'`4Y垬钀逌秗苸迉Lv剉N縹籰梪 2.NCCN4N奮瀃鯈cWS4Y垬钀Lv4N奮瀃鯈cWS2019.V1 Class a!b HNaS聰T€T籰梪0_薡錘aS聰籰梪剉,{1)Y w嵥Y圢墺YfUS梑400mg/m2 Y 亾忚l120min vQT蟢hT圢250mg/m2 Y 亾忚l60min01.齎FDA*gyb芉墺YfUS梑(u嶯籰梪錘聰{|o僫r籰梪1Y%崉vY裇bl忹y剉4Y垬钀逌秗苸迉Lv T€T籰梪 2.NCCN4N奮瀃鯈cWS4Y垬钀Lv4N奮瀃鯈cWS2018.V2 3.Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576.]x飩0Ws^ `$蕬Gr a$蕬Gr `$30mg a$10mg奩 Zg貧@垕S#1.蕬Gr30mg,qd 2.蕬6RBR 30-120mg/d[3] N1.齎FDA*gyb芉]x飩0Ws^蕬Gr0]x飩0Ws^蕬Gr(u嶯奩 Zg貧@垕S 2.-NNS;Sf[O嘫褃f[O 04N奮蕥梪cWS-嘫褃R孮 0 3.齎嘫褃;S^f[OACOGcWS,檒fW< 80mg胈汻p堩z7w嵥YBR蠎:N40mg bid 9hnc€譙 z颯瀀燫髞80mgb160mg g'Y賬o冨eBR蠎:N320mg,R!kg(u0X1.齎FDA騗yb芉,檒fW(u嶯籰梪b篘胈汻p堩z 2. 0-NNS胈@垺{舥Bg譥 02018,46(10) 0-N齎胈汻p堩z蕥璭孴籰梪cWS2018 0 3.-NNS;Sf[O 04N奮蕥梪cWS.胈@垺{R孮 0鰛蔞BR `$80mg a$160mg 謡?\舥線舥€M?\藛}v$1.80mg qd [5] 2.40mg[7]-160mg[6] 1.齎FDA*gyb芉,檒fW(u嶯謡?\舥線舥€M?\藛}v 2. 2017 齎b篘貧@垕S剺2 纇Km 膵0O孴tcWS 3.2012 KDOQIba'`線伵u膵0O孴t4N奮瀃鯈cWS 4.Hollenberg NK et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007 Sep;25(9):1921-6 5.Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003 6.Jin H, Zhang HN, Hou XL, et al: Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy. Eur Rev Med Pharmacol Sci 2016; 20(1):174-179. 7. Suzuki K, Souda S, Ikarashi T, et al: Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2002; 57:179-183.脌Lv孨縹籰梪 150-180mg/m2 ivd d1 蟢14d蛻Y o1.齎FDA*gyb芉 O藌f穅(u嶯脌Lv孨縹籰梪  2.NCCN4N奮瀃鯈cWS脌Lv2018 V3.0 2.'k2m縺$v匭褃f[O 02013 ESMO4N奮瀃鯈cWS脌Lv剉蕥璭0籰梪N彇繈 0 3. 0錯,g脌Lv籰梪cWS2014,{4Hr  0漁魚珒鳶 `$2.5mg a$5mg9sNz丩vN漁墡fWT€TO(u (u嶯籰梪輣蟸T纎 }譙SO3?` Her24?` O(ueg騠Ub?枺愹fU1Y%崉v蹚U\'`sNz丩v€  10mg蟢錯N!k鉙g賬o兠1.齎FDA騗yb芉迾<\N漁墡fWT€TO(u (u嶯籰梪輣蟸T纎 }譙SO3?` Her24?` O(ueg騠Ub?枺愹fU1Y%崉v蹚U\'`sNz丩v€0 2.NCCN4N奮瀃鯈cWSsNz丩v2018.V2 3. 0ABC2hQtZfgsNz丩vcWS 0 4. 0-N齎梑LvOSOsNz丩v蕥籰cWSN膲 02017t^Hr  1000mg ^y蟸蚹苸迉$v   l1.齎FDA*gyb芉鑜\(u_痵鱴p扂€(u嶯^y蟸蚹苸迉Lv 2. 0梑縺$vo僫r4N奮擽(uc黐烻R 0 2T赥洀剺2栭e25mg q6h 擽(uN厤菑48\鰁 a1.齎FDA*gyb芉2T赥洀(u嶯剺2栭e 2.-NNS;Sf[O. 4N奮蕥梪cWS. 嘫褃f[R孮[M]. 篘lkSu鶴Hr>y, 2007. 3.齎嘫褃;S^f[OACOGcWS僴'`觺爛巔$枡!k5mg/kgY 侓n鑜 ,{00206hT蔛KNT蟢8hT賬圢鴙 TBR蠎T1!k01.齎FDA騗yb芉駛+Y)R塙S梑(u嶯籰梪鵞8^膲籰梪蚐擽NEQR-N髞%N蛻;m≧'`僴'`觺爛巔 2.-NNS;Sf[O匭褃f[O 0巔莡'`爛舥蕥璭N籰梪剉qQ茓a翂 0 3.-NNS;Sf[O坢S舥f[RO巔莡'`爛舥f[膥 0駛+Y)R壔l梪KQWi`舥剉╟P児eHh2018t^  0 b篘Class I ?Q鍅Class a!ab篘Class a!a ?Q鍅Class a!b鰯Q\舥sQ倐巔+枡!k5mg/kgY 侓n鑜 ,{00206hT蔛KNT蟢8hT賬圢鴙 TBR蠎T1!k籰梪鰯Q\舥sQ倐巔1.齎FDA騗yb芉駛+Y)RfUS梑(u嶯鰯Q\舥sQ倐巔剉籰梪 2.駛齎螛n舥f[O/駛齎螛n舥kSuNN篘XTOSO 0BSRBHPR 擽(uuir6RBR籰梪鰯Q\舥sQ倐巔cWS 02012Hr 3.'k2m梑螛n舥T€遶 0EULAR 鰯Q\舥sQ倐巔o僫r籰梪t鷁畫 02011Hr骃N歂鷢剺2柦劘s{|o僫r_w崉v胈佉k'`1. cBR蠎詋骃N歂鷢絼痵o僫r=10-20:1 Y 侓n鑜 G1.齎FDA*gyb芉骃N歂鷢垟(u嶯剺2柦劘s{|o僫r_w崉v胈佉k'` 2.-N齎4N奮縺$vf[O-NNS;Sf[O@埐mf[RO 02013絼痵{|o僫r胈佉k'`2柣lcWS 0b篘Class a!a ?Q鍅 Class a!bb篘Class a!b ?Q鍅 Class a!bb篘Category A?Q鍅Category B脌Lv:1.齎FDA*gyb芉+}Ig噾(u嶯脌Lv 2.NCCN4N奮瀃鯈cWS脌Lv籰梪cWS2019.V1H1.T€Tz樎0NCCNcWS135mg/m2+}Ig噾孴z樎擳€(u 蟢 NhT蛻YN!k 2.USo兓l梪0N!k170mg/m2 鬾鑜24\鰁 蟢3hT1!k[5]M1.齎FDA*gyb芉+}Ig噾(u嶯玔垬Lv 2.NCCN4N奮瀃鯈cWS玔垬Lv2019.V3 3.NCCN4N奮瀃鯈cWS玔垬Lv4N奮瀃鯈cWS2018.V1 4.Moore, D. H . Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study[J]. Journal of Clinical Oncology, 2004, 22(15):3113-3119. 5.Mcguire W P , Blessing J A , Moore D , et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 1996, 14(3):792-5. +}Ig噾(}v藛}v觺T媁)l忹y'`饊z丩v T€T T壷N鑞\O:NN縹籰梪筫Hh1.齎FDA騗yb芉+}Ig噾(}v藛}v觺T媁)T€T T壷N鑞(u嶯b篘l忹y'`饊z丩v剉N縹籰梪 2.NCCN4N奮瀃鯈cWS饊z丩v4N奮瀃鯈cWS2019.V2 3.-NNS篘lqQ孴齎齎禰kSueP穅訷XTO 0饊z丩v蕥梪膲 02018  4. 04N奮縺$vf[Bg譥 02014t^4g,{19wS,{4g 0饊z丩v鼅T蕥籰-N齎N禰qQ茓2014t^Hr  0Uegx 5mg:100ml 5mgY 佽l\ 蟢t^N!kA1.齎FDA騗yb芉Uegx戯S(u嶯7u'`(崗u~g 2.-NNS;Sf[O(崗u~g孴w衯緐舥RO 0烻裇'`(崗u~g莡蕥梪cWS ( 2017) 0#黵畊'`線巔  b篘Class I ?Q鍅Class I 7Classa!b 7"黵畊'`線巔 b篘Category A ?Q鍅Category B 7b篘Category B?Q鍅Category C 7yr)R燫婼 } 7`$GrBRa$鑜\`$GrBR a$墊垟b$鑜\瞞m,{N)YBR蠎:N50mg/d齎Y魦ffN(u誰 ,{孨)Y:N100mg/d,{ N)Y200mg/d,{踁)Y300mg/d,{擭)Y400mg/dR2-3!k賬o ╟P傿R蠎400-800mg/d 錯BR蠎g貧:N800mg/d0c1.齎FDA*gyb芉kxU VdT籰梪b篘巔莡'`爛舥 2.-NNS;Sf[O 04N奮蕥梪cWS坢S鹼邁緐舥R孮 0 3.-NNS;Sf[O坢S舥f[RO巔莡'`爛舥f[膥 0巔莡'`爛舥蕥璭N籰梪剉qQ茓a翂(2018t^" S琋) 0 11.齎FDA*gyb芉簢匭o?u嶯籰梪b篘鸞8^鋟畊 2.-NNS;Sf[O 04N奮蕥梪cWS" 畍舥N'`舥R孮 0 厤o兞T魦ffN(uo冾vU_2019t^Hr  7^Nwo僨[O2019t^6g17錯裇^  7 8^(u剉US筽鑜\BR蠎:N1-4U[2] ' `$10mg/!k d1-4貧魜T筫Hh  a$10mg/!k d1-3-N魜T筫Hh   85mg/m2  85~130mg/m20鎷翂NCCNcWS  7.5mg/kg iv  NhT:NN梪 z[2]  5-6mg im q12hs%4!k[1 2] 1.齎FDA*gyb芉鍕(u誰 2.-NNS;Sf[O嘫褃f[RO. 閑剉4N奮蕥璭N籰梪cWS2014 . -NNS嘫褃Bg譥.2014,49(7):481-484. 3< .-NNS;Sf[O. 4N奮蕥梪cWS:嘫褃f[R孮[M]. 篘lkSu鶴Hr>y, 2007. 4.ACOG, Practice Bulletin No. 171: Management of Preterm Labor.Obstet Gynecol. 2016 Oct;128(4):e155-64. /0 %50 mg/m2 q28d[2] 20-30mg/m2 q21d[3]     % USo?5mg/m2 Y 亾忚l Y 亾忚l鰁魰N\嶯1\鰁 蟢21)Y蛻Y賬o  $ 0 T€Tz樎0l?\'VvUO(u剉3hT筫Hh-NY壷N[?5mg/m2 ,{N)Y賬o Y 亾忚l鰁魰N\嶯1\鰁  # uS鈃Lv 60^75mg/m2T€TaS聰AUC=5^6 蟢3hT1!k[2]   ? 皊╟PO(u9eo侶rDCF筫Hh Y壷N[岯R蠎:N40mg/m240mg/m2Y 侓n鑜 蟢 NhT賬oN!k T€T5-l?\'VvU孴z樎擺2] " # ; Y壷N[?5mg /m2 w嵥YBR蠎0.25g/d 魚cBR蠎0.25^2g/d[1 2]   cSO蛻蟢錯3^ 5mg/kg R2!k鉙g[2]   cSO蛻蟢錯2.5^ 5mg/kg R2!k鉙g[2]   cSO蛻蟢錯2^ 4mg/kg R2!k鉙g[2]  0.5-1.0g/m2 蟢3-4hTN!k % 1g/m2 鬾鑜30min R+R(W,{1)Y孴,{8)Y賬o  NhT:NN梪 z[2]   ! $ % 1g/m2 鬾鑜30min R+R(W,{1)Y孴,{8)Y賬o  NhT:NN梪 z[2]   ! * 1000mg/m2Y 侓n鑜30R煍 蟢hTN!k 迯韣孨hT 彇TOo`NhT 蟢 NhT蛻YN!k  1.0g/m2 iv 蟢21d蛻Y   0 鉙g0寑墍鑜\0sQ倐T亝QbY 佽l\GW gHe 蟢hT賬o?!k 8^(uBR蠎:N7.5^20mghT[4]0 + . K 颯菓(uhQ珟孴@\钀賬o hQ珟(uo儎v8^(uBR蠎:N cSO蛻N!k0.4mg/kg 蟢錯1!k 寑鑜 5錯:NN梪 z 鍌US!kBR蠎寑鑜8^(u1mg/kgb50mg/m20 H I  籹僼SO鑜\0.3mg 蟢gN!k   ╟P傿R蠎:N375mg/m2 BSA   蟢hT375mg/m2 qQ籰梪4hT  N (W_薡FCS梪剉MR1)Y圢Y 亾忚l375mg/m2 (W,{2-6*NS梪梪 z蟢28)Y:NN梪 z 剉,{1)Y圢Y 亾忚l500mg/m20螿蠎剉FCR筫Hh耂€cWS[2]  =  375mg/m2 qw qQ4hT;b1000mg 2hTT蛻Y1!k   375mg/m2 qw qQ籰梪4hT  G 'k2mqQ茓a翂╟P儎v顅hBR蠎1.5-2.5mg/kgd  髞\擽(u3-6*Ng -N齎€BR蠎1.0-1.5mg/(kgd)  gHe[3]D 蟢錯鉙g2mg/kg[2]  50^100mg/d [3]  | 4N奮o僫r籰梪f[b篘1.5^2.0g/d R2!kg 3-6*NgT_薡ba螿蠎0魚cBR蠎0.5-0.75g/d 魚c鰁魰1-2t^ ?Q鍅20^30mg/kg.d b800-1200mg/(m2.d) g'YBR蠎1g 蟢錯$N!k 籰梪鰁魰12-24*Ng0_ ` ' 蟢!k賬o?0-100mg/m2 蟢梪 z賬oN!k 髞\\Po?hTT蛻Y NN*N梪 z0   Sm2.5mg/ml 'Yby佽恘廇m鑜\[1] 10~30mg qd[1] Z w嵥YBR蠎蔛瀀燫BR蠎:N20mg/d:N螿\No偼S擽钀R€颯螿JS  8^(u顅hBR蠎:N40-60mg/d 8^(ug'YBR蠎:N80-120mg/d0020齎匭魦ffN慴翋莡g'YBR蠎:N40mg/dD G j (W_薡>e梪MR剉NhT w嵥Y圢400mg/m2 Y 亾忚l120ming'Y搹鑜惁^:N10mg/min 0彇T剉>e梪g魰6-7hT  蟢hT圢250mg/m2 qw Y 亾忚l60ming'Y搹鑜惁^:N10mg/min 0  J K w USo兓l梪0w嵥Y圢400mg/m2 Y 亾忚l120ming'Y搹鑜惁^:N10mg/min 0彇T蟢hT圢250mg/m2 qw Y 亾忚l60ming'Y搹鑜惁^:N10mg/min  c韣(uo凈v0R緐舥蹚U\b鶴皊N齹€譙剉襨'`蚐擽0   9 : (W_薡錘聰{|o僫r:N鶺@x剉S梪孴5-FU籰梪剉,{1)Y w嵥Y圢400mg/m2 Y 亾忚l120ming'Y搹鑜惁^:N10mg/min 0vQT蟢hT圢250mg/m2 qw Y 亾忚l60ming'Y搹鑜惁^:N10mg/min  c韣(uo凈v0R緐舥蹚U\b鶴皊N齹€譙剉襨'`蚐擽0 $ % N O 1.5g/m2[2] - 癳厪㏑S梪50mg/m2 d1 T€TaS聰 AUC 2 d1 Y 亾忚l 迯韣5hT[2] ( + 0 100mg/m2 Y 亾忚l30R煍 (W,{1)Y0,{8)Y孴,{15)Y賬o 蟢21)Y:NN梪 z0T€TaS聰0  5 125mg/m2 Y 亾忚l30-40R煍 (W,{1)Y0,{8)Y孴,{15)Y賬o 蟢28)Y:NN梪 z0T€T T壷N鑞0  +}Ig噾}v藛}v觺T媁  7肳"}蒪U 7eY騠絸 7鑜\瞞 7O鄐US梑 7峴|潃 }爺 7剺2朰 丂hh^X螛i杽v裇u 7畍 N鑜\ 741.FDA魦ffN騗yb鑜NxlfaS~g颯(孨aO(u嶯3g劅錘 N?Q鍅 2.-N齎yr擽'`畍巔蕥梪cWS2014Hr  7 ^楐uFT媁@垺{'`鍂湒峹 7?峉O鑜\瞞Y詆詋f 7\苸迉簚Lv  7Y壷N[ 7b篘Classa!a ?Q鍅Classa!b 7b篘Classa!b ?Q鍅Classa!b 7l?\'VvU 7爛秐Gr 7骻.l鷛!TvU 7Tf€Z憃 7鰛蔞/GrBR 75mg 7#w嵥YBR蠎5-60mg/d,9hnc*NSO蚐擽(ug\BR蠎韜梪 z魚c(俌<3g) 72Y 佽l\ 1.3 mg/m2 3hTN*N梪 z,{1,4,8,11)Y賬o12-21)Y\Po  qQ6*N梪 z 7]x飩0Ws^ 7褢R 7漁緩蒪IY 71000mg 7駛+Y)R塙S梑 7墊垟 7aS鬩蒪@l 7\Y鑜 1.FDA魦ffN颯(WFDA榌Q N N}http://www.fda.gov/ 2.,g顅U_臢汷;S梪:g刧耂€ 厤魦ffN(uo償^ cck膲Am z膲儭{t 3._(u,g顅U_匭筟鰁鲖鑜f鶴Y0 7A`$25mg a$50mg b$75mg c$100mg d$150mg 7GrBR 7YHY蘐P 71.齎FDA騗yb芉漁緩蒪IY(u嶯b篘寑?'`"}lxS莡ALS 剉籰梪 2.Writing Group & Edaravone (MCI-186) ALS 19 Study Group: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16(7):505-512. 7v1.齎FDA*gyb芉O鄐US梑(u嶯籰梪鐍裇嶯t^劅鴙sQ'`臑慹豐'`剉 佨~渷癳u@垺{S 2. 02015齎27 kg/m2 Tv^髞\Ny槬€謤v^裇莡剉€b€BMI>30kg/m2剉US瘇'`謤€  * +  7"10-NNOqS%`'`託'`}v@埮u剉駤黐S梪 20緰籰'`/Y裇'`%`'`託'`}v@埮u 71.齎FDA騗yb芉S N噾(u嶯2u秗羍z仧R齹螿惽u_w崉vNO檾@埱u 2.-NNS;Sf[O(崗u~g孴w衯緐舥RO 02006t^2u秗羍z仧R齹螿惽u孴GP'`2u秗羍z仧R齹螿惽u蕥籰cWS 0 3.2018t^ 02u秗羍z仧R齹螿惽u4N奮蕥梪cWS 0 7! cSOh坆楋yN錯1000mg/m2 迯(u1-4d,鎷翂NCCNcWS   7500mg 71.駛齎N夗sYr魦ffN騗yb芉峴|潃 }爺鑜\瞞(u嶯剺2朰 丂hh^X螛i杽v裇u 2<.NICEcWSVenous thromboembolism in over 16s Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. 3.Venous thromboembolism in over 16s Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism 7? J7j?i8? 弃欲H?h+@K VEv扢 Q*璗匲2W/bX_餤|]y|ay 糴騢m>n;╫Ar>苧羦{鑩;{>}鼅▉ 磦 6鎱B湁v鄫 N(J$: ?M暉L轄 佟 cw.'彫F姱A0P趾sT犊S嗔} 疵Q #啡Th芪y秆U犜=2炮>垒9庍距7 玮` 椾渝L茬+&蛛O囲|轲bY硝HdJdB 7 (  ;  .i? ? ;'v#*^[1P3:6u?<0轧KAb 闒豀DJ[圞M*QQh沇cc PK!檗?[Content_Types].xml瑧薔?E鱄鼉?J湶@%閭菐洽|廊?韶钵UL襎B l,?鳛;鉹得槣B+$G]ミ7O侪V墎 |漭f LPg擎儑黮培坩?c xc啫 穻掊?.嗟閩媖?鍿I懐菈<`岊2頛纔巳餪欶钹|j鈔#t鑺軫︰囝tJ\.?秇蔻(??枮呵;fw+$郘皯纛ogJdh-I?3A(禃泝晦.．Yw稹崉Q〥壦%訪齄挶媎*a始n垍p佘?_ｈ譇C躤?牫腇rI?燐?賏鉽寬 ?ilb?cX⑷慌 ~漓'D]CP憾躻 妒}?)-埡3鍘Z^锰Z魁!琔暂韯?*x徕帝咙bT垌厥抽'围foIプ狺囑蹵郁喦a?}愭异亏壹頨緓A^h0瘸f鹠禁N謓綠勔緶Q?酤[@ {0豉嚤I _論 ,\膽恶8摕鱟4伣{臰N"懟巹7a螌z亻[衢49`av娆T赠2佷b糪+漆 3t奖8G?跦焪旐YH羖嶚燡扊]C$籼.凟恿獠r?/ 燰T禙l╖~ &`?Dq敃z^]]虌篸Z+ ?皑tSq];=5籰⒁ c官$tft1 q晋砧ih湹滞EI-z*y. 嵥ocq轟冚?性T 歾G-烤Y?營临?X;Bmi嵿=X y隼烥Y&\q杙-:$Db頠挻|5 4⒐U6@轞rM悤w?2峱 筒#*淤%(|位邳黗e搔P額yC:宸,盳＂/x*Y6C? ![テ斔RPl袸岒巄妝識^醒WE尗|螑P#%y#F欼岛i?2k活蒄*s唄.zΕ*猭篣虋0oK更_?X蚐 硪祓檛/Kns畊K麆@聥?侯)侫m挞耙靯灶 濦?M翽茼R迠 冪挈`芳jah4遅闘脒0踢仞>圙掬N簲痣G?觌=I!趖?PK!褠煻'theme/theme/_rels/themeManager.xml.rels剰M ?匃倃oo雍?輬协勪56?$Q祉?.嘺緳i粭澤c2?h:闀q毩m胳嶡RN壻;d癭値o7g慘(M&$R(.1榬'J摐袏T鶂?V?＆A然蠬鱱}狇|?絙{朠?除8塯/]As賲(⑵锑#洩L蔥汉倪PK-!檗?[Content_Types].xmlPK-!ブх6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!T?Atheme/theme/theme1.xmlPK-!褠煻' theme/theme/_rels/themeManager.xml.relsPK]  g2蓘 ,矖埊疫@D  d褚MbP?_*+€%&ffffff?'ffffff?(?)?MHP ColorLaserJet M153-M154 PCL€ 4dXX适CourierHelvetica X@PJL SET GUISTARTJOB=1 @PJL SET GUIENDJOB=1 FC:\WINDOWS\SYSTEM32\SPOOL\DRIVERS\X64\3\HPNIAE2A_X64CFG.XML錧係貫緥nA€K€n@s@U _ - 2Arial||||" dXX333333?333333?&<3U} R} € }  }  }  } } ?o兞T酧o`@w€H€H    F'eeF FFF WU XXXXXXXXXXXXX YV ZZZZZZZZZZZZZ U U VV UVVVVVV  U  VVGV E E E E E E E E  E  E  E  E EG~ P? I IV F IFFFF  F?  I  F;  F IA~ P@ I IV F IFFFF  F?  I  F;  F; IA~ P@ I IV F IFFFF  F?  I  I@  F; IA~ P@ I IV F IFFFF  F  I  I@  F; IA~ P@ F IV F FFFFF  FW  F  F  F& FA~ P@ F  FB F F! F F" FF F# F$ F; F& F A~ P@ F  FB F F% F F FF F& F' F; F& F A~ P @ F  FB F F( F F) FF F* F+ F; F& F A~ P"@ F  FB F F, F F- FF F. F/ F; F& F A~ P$@ F  FB F F0 F F FF F1 F2 F; F& FA~ P&@ F  FB F F3 F F4 FF  F5  F6  F;  F& FA~ P(@ F7 J8 F9 F:JFFF  F;  F<  F@  F; JAA~ P*@ F F" F= F>FFFF  F?  F@  F&  F& FA~ P,@ FA FB FG FBF FC FF  FD  FE  F&  F& FA~ P.@ FA FB FF FGF F FF  FH  FI  FJ  F; FA~ P0@ FA FB FK FLF F FF  FM  FN  F;  F& FA~ P1@ FO FB F F3F FP FF  FQ  FR  Fm  F& FA~ P2@ FO FB F FSFFFF  FX  FT  F;  F& FA~ P3@ FO FB F FUFFFF  FV  FW  F;  F& FA~ P4@ F F" F FFFFF  F  F  FL  F FC~ P5@ FX FV FY FZFFFF  FY  F[  F;  F& FA~ P6@ FX FV FY F\FFFF  FZ  F]  F^  F_ F`A~ P7@ Fa FV F FbFFFF  Fc  Fd  F;  Fn FA~ P8@ Fe F" Ff FgFFFF  Fh  F  F;  F& FA~ P9@ Fe Fi Fj FkFFFF  Fl  Fm  F&  F& FA~ P:@ Fe F" Ff FnFFFF  Fo  Fp  F;  F& FA~ P;@ Fe F Fj FqFFFF  Fr  Fs  F;  F FA~ P<@ Fe F Ff FtFFFF  Fu  Fv  F@  F; FADZl22l !"#$%&'()*e+,-./0123e456e7e8'9e:e;<=>?~ P=@ Fe F" Fw Fx FFFF F[ Fy Fm Fn F A~ !P>@ !F !F" !F !F!FFFF ! F ! F ! F ! FFC~ "P?@ "F "F "F "F "F"F "F"F " F " F " F " FFC~ #P@@ #Fz #FB #F{ #F|#FFFF # F} # F~ # F; # F& #F#A~ $P€@@ $F $F $F $FF $F $FF $ F $ F $ F@ $ F* $F$C~ %PA@ %F %F€ %F %F%FFFF % F % F % F; % F& %F%A~ &P€A@ &F &F. &F &F&FFFF & F & F & F@ & F@ &F&A~ 'PB@ 'F 'F 'F 'F'FFFF ' F ' F ' F; ' F; 'F'A~ (P€B@ (F (F" (F (F(FFFF ( F\ ( F] ( F ( FFC~ )PC@ )F )F. )F )F )FF )F)F ) F ) F ) F ) F )F)A~ *P€C@ *F *F. *F *F*FFFF * F * F * F; * F; *FA*A~ +PD@ +F +F. +F +F+FFFF + F + F + FJ + F; +FA+A~ ,P€D@ ,F ,F ,F ,F,FFFF , F^ , F , F , F ,F,C~ -PE@ -F -F -F -F-FFFF - F - F - F - F -F-C~ .P€E@ .F .F" .F .F.FFFF . F_ . F . F; . F& .F.A~ /PF@ /F /F" /F /F/FFFF / F` / F / F; / F; /F/A~ 0P€F@ 0F 0F" 0F 0F0FFFF 0 F_ 0 F 0 F 0 F 0F0A~ 1PG@ 1F 1F" 1F 1F1FFFF 1 F_ 1 F 1 F; 1 F& 1F1A~ 2P€G@ 2F 2F" 2F 2F2FFFF 2 Fa 2 F 2 F@ 2 F& 2F2A~ 3PH@ 3F 3F" 3F 3F3FFFF 3 Fb 3 F 3 F; 3 F& 3F3A~ 4P€H@ 4F 4F" 4F 4F4FFFF 4 Fc 4 F 4 F 4 F; 4F4C~ 5PI@ 5F 5FB 5F 5F5FFFF 5 F 5 F 5 F@ 5 F; 5FA5A~ 6P€I@ 6F 6FB 6F 6F6FFFF 6 F 6 F 6 F; 6 F; 6F6A~ 7PJ@ 7F 7FB 7F 7F7FFFF 7 F 7 F 7 F; 7 F; 7F7A~ 8P€J@ 8F 8FB 8F 8F8FFFF 8 F 8 F 8 F 8 F 8F8A~ 9PK@ 9F 9FB 9F 9F9FFFF 9 F 9 F 9 F 9 F 9FN9B~ :P€K@ :F :FB :F :F:FFFF : F : F : F; : F& :F:A~ ;PL@ ;F ;F" ;F ;F;FFFF ; F ; F ; F; ; F& ;F;A~ <P€L@ <F <F" <F <F<FFFF < F < F < F < F& <F<C~ =PM@ =F =F =F =F=FFFF = F = F = F@ = F; =F=A~ >P€M@ >F >F >F >F>FFFF > F > F > F@ > F; >F>A~ ?PN@ ?F ?F ?F ?FL?F ?F ?FF ? F ? F ? F@ ? F; ?F?ADl@FA'BeCeDEFeGHIJKeLMNO PQReS TUVWXYFZ[\e]^_ ~ @P€N@ @F @F. @F @F@FFFF @ Fd @ F @ FJ @ F; @F@A~ APO@ AF AF. AF AFAFFFF A Fe A F A F; A F& AFAA~ BP€O@ BF BF. BF BFBFFFF B Ff B F B F; B F& BFBA~ CPP@ CF CF CF CFCFFFF C Fg C F C F@ C F; CFCA~ DP@P@ DF DF DF DF DFF DFDF D Fh D F D F; D F& DFDA~ EP€P@ EF EF EF EFEFFFF E Fh E F E F; E F; EFEA~ FP繮@ FF FFB FF FF FFF FFFF F F F F F F; F F FFFA~ GPQ@ GF GFV GF GF GFF GFGF G Fi G F G F; G F& GFGA~ HP@Q@ HF HFV HF HFHFFFF H Fj H F H F@ H F@ HFHA~ IP€Q@ IF IFV IF IFIFFFF I F I F I F I F& IFIA~ JP繯@ JF JFV JF JFJFFFF J Fj J F J F J F; JFJA~ KPR@ KF KFV KF KFKFFFF K Fk K F K F K F KFKA~ LP@R@ LF LF" LF LFLFFFF L Fl L F L F; L F& LFLA~ MP€R@ MF MF MF MFMFFFF M F M F M F; M F& MFMA~ NP繰@ NF NFV NF NF(NFFFF N F N F N F N F& NFNC~ OPS@ OF OFP OF OFOFFFF O Fm O F O F O F OFOA~ PP@S@ PF PFQ PF PFPFFFF P K P F P F; P F& PFPA~ QP€S@ QF QF" QF QFQFFFF Q Fn Q F Q F Q F QFQA~ RP繱@ RF RFB RF RFRFFFF R F R F R F& R F& RFRC~ SPT@ SF SF" SF SF SF SFFF S F S F S F@ S F; SFASC~ TP@T@ TF TF" TF TF    ???TFFFF T F T F T F; T F& TFTA~ UP€T@ UF UF" UF UFUFFFF U F U F U F; U F& UFUA~ VP繲@ VF VF" VF VFnVFFFF V F V F V F; V F& VFVA~ WPU@ WF WFB WF WFWFFFF W F W F W F@ W F; WFWA~ XP@U@ XF XFB XF XFXFFFF X F X F X F; X F& XFAXA~ YP€U@ YF YF YF YFYFFFF Y F Y F Y F Y FFC~ ZP繳@ ZF ZFB ZF ZFZFFFF Z F Z F Z F; Z F; ZFZA~ [PV@ [F [FB [F [F[F [F [FF [ F [ F [ Fm [ F& [F[A~ \P@V@ \F \FB \F \F3\F \FP \FF \ FR \ F \ Fm \ F& \F\A~ ]P€V@ ]F ]F ]F ]F0]FFFF ] F ] F ] F; ] F& ]F]A~ ^P繴@ ^F ^FB ^F ^F^FFFF ^ F ^ F ^ F; ^ F; ^F^C~ _PW@ _F  _FB _F  _F _FFFF _ F  _ F _ F; _ F; _F_ADl`abcdefg heiejkelFm'nopFqersFtuvwxeyzs{ |}~~ `P@W@ `F `FB `F `F`FFFF ` F ` F ` F; ` F& `F`A~ aP€W@ aF aF" aFG aFaFFFF a Fo a F a F; a F; aFaA~ bP繵@ bF bF" bFG bFbFFFF b F b F b FJ b F; bFbA~ cPX@ cF cF" cFG cFcFFFF c F c F c F; c F& cFcA~ dP@X@ dF dF" dFG dFdFFFF d Fo d F d F; d F; dFdA~ eP€X@ eF eF" eF eF eF eF eFeF e F e F  e F! e F& eFAeA~ fP繶@ fF" fF# fF$ fF3fF fF% fFF f F& f F' f F( f F) fF*fA~ gPY@ gF" gF+ gF, gF!gF gF- gFF g F. g F/ g FJ g F; gFAgA~ hP@Y@ hF" hF+ hF, hF hF hF0 hFF h F1 h F2 h F( h F) hF*hA~ iP€Y@ iF3 iF" iF iF4iFFFF i Fp i F5 i F; i F& iFiA~ jP繷@ jF3 jF" jF6 jF7jFFFF j Fq j F8 j F; j F& jFjA~ kPZ@ kF3 kFi kF9 kF:kFFFF k Fr k F; k F; k F; kFkA~ lP@Z@ lF3 lF" lF6 lF<lFFFF l Fs l F= l F> l F lFlA~ mP€Z@ mF3 mF" mF6 mFmFFFF m F? m F@ m F; m F& mFmA~ nP繸@ nF3 nF" nF6 nFnFFFF n Ft n FA n F; n F& nFnA~ oP[@ oF3 oF" oF6 oFBoFFFF o Ft o FC o F; o F& oFoA~ pP@[@ pJD pF< pJE pJFpJJJF p JG p FH p F p FFA~ qP€[@ qFI qFB qFY qFJqFFFF q Fu q FS q F! q F& qFqA~ rP繹@ rFI rFB rFY rFKrFFFF r Fv r FL r F; r F& rFrA~ sP\@ sF sF sF sFqsFFFF s F s F s F s F sFsC~ tP@\@ tFM tFB tFN tFtFFFF t FO t FP t F; t F& tFtA~ uP€\@ uFQ uF uFR uFSuFFFF u FT u FT u F; u F& uFuA~ vP繺@ vFQ vFU vFV vFW vF vFFF v Fw v FX v F; v F& vFvA~ wP]@ wF wFB wF wF wF wFFF w F w F w F w F wFwC~ xP@]@ xFY xFZ xF[ xFxFFFF x F\ x F] x F@ x F; xFxA~ yP€]@ yF^ yFB yF_ yFyFFFF y F` y Fa y FJ y F; yFAyA~ zP繻@ zF zFB zFb zFczFFFF z Fx z Fd z Fe z Ff zFgzA~ {P^@ {F {F {F {F{FFFF { F { F { F { F {F{C~ |P@^@ |F |F |F |F|FFFF | F | F | FK | F |FM|C~ }P€^@ }Fh }F }Fi }Fj}FFFF } Fk } Fl } F@ } F; }F}A~ ~P繼@ ~Fh ~F ~Fi ~Fm~FFFF ~ Fn ~ Fo ~ F@ ~ F; ~FA~A~ P_@ Jp JB J JqJFFF  Jr  Fs  F;  F& FADl€e'Fe'Feee~ €P@_@ €Ft €FB €Fu €Fv€FFFF € Fw € Fx € Fm € Fn €F€A~ P€_@ Fy FV FG FzFFFF Fy F{ F FFA~ P繽@ F F| F F}FFFF F F~ F; F& FA~ P`@ F F F F€FFFF F F F; F; FA~ P `@ F F F F3F F FF F F F; F& FA~ P@`@ F F F FFFFF F F F; F& FC~ P``@ F FB F FFFFF F F F F@ FA~ P€`@ F FB F FFFFF F F F F; FA~ P燻@ F| F' F} F~FFFF F F€ F F& FC~ P繾@ F F" F F FF FF Fz F F F; FA~ P郹@ F FV F FFFFF F F F; F; FA~ Pa@ Fy FB F FFFFF F F F; F& FA~ P a@ Fy FB F FzFFFF F F{ F@ Fm FC~ P@a@ F FB F_ FF F FF F F F FFA~ P`a@ F FB FG FF F FF F F F; F; FAA~ P€a@ F F. F FFFFF F F F; F& FA~ P燼@ F F. F F(FFFF F F F; F; FA~ P繿@ F F. F FFFFF F F F F& FA~ P郺@ Fu FB Fv Fw FF F3F Fx F F F FC~ Pb@ Fo FB F FFFFF F F F; F& FA~ P b@ Fo FB F FFFFF F F F; F& FA~ P@b@ Fo FB F FF F FF F F F; F& FA~ P`b@ Fo FB F FFFFF F F F@ F; FA~ P€b@ Fo FB Fp FqFFFF Fr Fs F F FtC~ P燽@ F FB FY FL F F FF F F F@ F; FA~ P纀@ F FB FY FFFFF F F F F@ FA~ P郻@ F FB FY FFFFF F F F F FA~ Pc@ F FB FY FFFFF F F F F@ FA~ P c@ F FB FY FFFFF F F F; F& FA~ P@c@ F FB FY FUF F FF F F F F FgA~ P`c@ F FV F F F F FF F F F F FA~ P€c@ Fh FB Fi Fj Fk FFF Fk Fl Fm Fn FCD&l e eFe'eee7ee~ P燾@ L FB F FF F FF F F F; F; FA~ P纁@ F` FB Fa FbFFFF Fc Fd Fe Ff FgC~ P郼@ F] FB FG F^FFFF F{ F_ F F& FC~ Pd@ F FB Fu FFFFF F F F; F& FA~ P d@ F F" F FF F FF F F F; F& FA~ P@d@ FO FV FW FX FYF FZF F[ F\ F FN FC~ P`d@ J FB J JJ J JF J F F; F& FA~ P€d@ F F. F FFFFF F F F F FA~ P燿@ FO F. FY FFFFF F F F; F& FA~ P纃@ FO F. FP FQFFFF FR FS F FFC~ P郿@ FO F. FP FTFFFF F FU F FFC~ Pe@ F FV F F FF F3F F F F F FA~ P e@ F F. F FFFFF F F F F; FA~ P@e@ F F. F FFFFF F F F F FA~ P`e@ F F< F FFFFF F F F FFA~ P€e@ F F< F FFFFF F F F FFA~ P爀@ F FB F FF F FF F F F F FA~ P纄@ F FB FK FLFFFF F| F F F FA~ P鄀@ F F" F FFFFF F} F F@ F; FA~ Pf@ F F" F F FFFF F~ F  F; F& FA~ P f@ F F" F F FFFF F F  F F& FA~ P@f@ F F" F F$FFFF F F F; F& FA~ P`f@ F F F FF F FF F F F; F& FA~ P€f@ F FB FG FK FF F3F FL FM F& FN FC~ P爁@ F F. F FFFFF F F FJ F; FA~ P纅@ F F F FFFFF F F F; F& FA~ P鄁@ F FB FG F0 FH F2 F3F FI FJ F6 F7 FC~ Pg@ F FB FC F0 FD F2 F3F FE FF F6 F7 FC~ P g@ F F" F  F FFFF F  F  F; F FA~ P@g@ F F" F= F FFFF F! F" F; F& FA~ P`g@ F F F= F>FFFF F? F F@ F; FAC~ P€g@ F# FB F$ F%FFFF F& F' F; F& FAD lF' e')@~ P爂@ F8 F" F( F) F* F+ F+F F€ F, F; F& FA~ P纆@ F8 F" F F9FFFF F F: F; F& FC~ P鄃@ F- FB F F.FFFF F/ F0 F; F& FA~ Ph@ F FV F F1F F FF F2 F3 F4 F5 FA~ P h@ F FV F F6FFFF F7 F8 F@ F& FA~ P@h@ F9 F F F:FFFM F; F< F= F> F?A~ P`h@ F F. F/ F0 F1 F2 F3F F4 F5 F6 F7 FC~ P€h@ F! F" F# F@ FF FF F FA F; F& FA~ P爃@ F! F" F# Fz FF FF FB FC F; F& FD~ P纇@ F! F" F# F$FFFF F F% F F& FC~ P鄅@ F! F" F# F(FFFF F F) F F* F+C~ Pi@ F! F" F# F,FFFF F F- F F* F+C~ P i@ F FV F FFFFF F F F; F& FA~ P@i@ F FV F FFFFF F? F F; Fn FA~ P`i@ FD FV F FEFFFF F FF F; F; FA~ P€i@ F F F FFFFF F F F FFC~ P爄@ F F F FFFFF F F F F FC~ P纈@ F F F FFFFF F F F F FC~ P鄆@ FG F" FH FF F FF FI FJ F; F& FA~ Qj@ N N N NNNNN N N N NN S"TTTTTTTTTTTTTO.h>@dTR:  7J::猩陏寕K O0W^ Sheet2!C339J猩陏寕K  O藌f穅 Sheet2!C331ggD HXp yangusWindows 用户Microsoft Excel@€??`髟@埭Z1?胀諟.摋+,D胀諟.摋+,HP X`hpx  汇总 工作表$([c _PID_HLINKSKSOProductBuDocumentSummaryInformation8CompObjhildVerA po Sheet2!C331po Sheet2!C3392052-11.1.0.8696?  FMicrosoft Excel 2003 工作表Biff8Excel.Sheet.8?瞦